OFFICE OF ENVIRONMENTAL HEALTH HAZARD ASSESSMENT

Air Toxics Hot Spots Program

1-Bromopropane

Cancer Inhalation Unit Risk Factor

Technical Support Document for
Cancer Potency Factors
Appendix B

December 2022

Air and Site Assessment and Climate Indicators Branch
Office of Environmental Health Hazard Assessment
California Environmental Protection Agency

Page Intentionally Left Blank

1-Bromopropane

Cancer Inhalation Unit Risk Factor

Technical Support Document for Cancer Potency Factors
Appendix B

Prepared by the

Office of Environmental Health Hazard Assessment

Lauren Zeise, Ph.D., Director

Contributors

Daryn E. Dodge, Ph.D.

James F. Collins, Ph.D., DABT

Technical Reviewers

John D. Budroe, Ph.D.

Executive Reviewers

Vincent Cogliano, Ph.D.

David Edwards, Ph.D.

Kannan Krishnan, Ph.D.

December 2022

TABLE OF CONTENTS

Preface iv

I. PHYSICAL AND CHEMICAL PROPERTIES 1

II. HEALTH ASSESSMENT VALUES 1

III. CARCINOGENICITY 1

NTP Cancer Bioassay 1
F344/N rats 3
B6C3F1/N mice 7

Toxicokinetics 9
Rodent models 9
Toxicokinetics in children and adults 14

Genotoxicity 17
DNA strand-break tests 17
DNA Adduct formation in vitro and in vivo 19
Induction of DNA repair 20
Bacterial mutation tests 20
Mammalian cell gene mutation tests 21
Chromosomal damage 22
Transgenic rodent mutation assay 23

Dominant lethal mutations in rodents 25

Other Supporting Data 26
Cancer Bioassays with Structurally Related Compounds 26
Genotoxicity of 1-BP metabolites 26
Immune System, Oxidative Stress, and Cancer 27
Induction of cancer stem cells in colorectal cancer 27

IV. CANCER HAZARD EVALUATION 28

V. QUANTITATIVE CANCER RISK ASSESSMENT 29

Effective Tumor Incidences 29

Cancer Slope Factor Derivation 31

Inhalation Unit Risk Factor 35

VI. CONCLUSIONS 35

VII. REFERENCES 36

List of Acronyms

AIC	Akaike Information Criterion
ANOVA	Analysis of Variance
1-BP	1-Bromopropane
BMD	Benchmark dose
BMDS	Benchmark dose modeling software
BMR	Benchmark dose response
BR	Breathing rate
BW	Body weight
CAS	Chemical Abstracts Service
CEBS	Chemical Effects in Biological Systems
CF	Conversion factor
CO_2	Carbon Dioxide
CSF	Cancer slope factor
CTI	California Toxics Inventory
CYP	Cytochrome P450
CYP2E1	Cytochrome P450 2E1 isozyme
DBCP	1,2-dibromo-3-chloropropane
DNA	Deoxyribonucleic acid
FCM	Flavin-containing monooxygenase
GSH	Glutathione
GST	Glutathione-S-transferase
IL	Interleukin
iNOS	Nitric Oxide Synthetase
IUR	Inhalation unit risk
IR	Inhalation rate
IARC	International Agency for Research on Cancer
IV	Intravenous
NO	Nitric Oxide
NTP	National Toxicology Program
OEHHA	Office of Environmental Health Hazard Assessment
PBPK	Physiologically-based pharmacokinetic
ppm	parts per million
PrCys	S-propylcysteine
TNF	Tumor necrosis factor
TRI	Toxics Release Inventory
TWA	Time-weighted average
US EPA	United States Environmental Protection Agency
VOC	Volatile organic compound
WT	Wild-type

Preface

This document summarizes the carcinogenicity data and the derivation of a cancer inhalation unit risk factor for 1-bromopropane (1-BP). Cancer unit risk factors are used to estimate lifetime cancer risks associated with inhalation exposure to a carcinogen. The National Toxicology Program (NTP) conducted chronic inhalation toxicity and carcinogenicity bioassays of 1-BP (Morgan *et al.*, 2011; NTP, 2011) and found evidence of carcinogenicity in rats and mice. Consequently, OEHHA has derived a cancer inhalation unit risk factor (IUR) from the NTP animal data for use in the Hot Spots program.

OEHHA is legislatively mandated to develop guidelines for conducting health risk assessments under the Air Toxics Hot Spots Program (Health and Safety Code Section 44360(b)(2). In implementing this requirement, OEHHA develops IURs for carcinogenic air pollutants listed under the Air Toxics Hot Spots program. The 1-BP IUR was developed using the most recent "Air Toxics Hot Spots Program Technical Support Document for Cancer Potency Factors", finalized by OEHHA in 2009 (OEHHA, 2009). Literature summarized and referenced in this document covers the relevant published reports, and relevant unpublished studies reviewed and supported by authoritative bodies, for 1-BP through spring 2021.

The PubMed database was used to search for relevant 1-BP articles (PubMed, 1996). Keywords included 1-bromopropane, propyl bromide, and the CAS Registry Number (106-94-5). Professional judgment was used in determining document inclusion (and exclusion) in this report. Individual studies summarized herein were primarily those that would be useful for deriving or supporting an IUR for 1-BP, including experimental animal carcinogenicity studies, human cancer studies, and genetic toxicity studies. Key 1-BP studies investigating human exposure, toxicokinetics, and mechanism of carcinogenicity were also summarized in this report.

1-BP has been proposed to be added to the list of substances for which emissions must be quantified under the OEHHA Air Toxics Hot Spots Program in 2021, and is a reportable chemical under the US EPA Toxics Release Inventory (TRI) program (TRI, 2015). 1-BP is listed as a chemical known to the State to cause cancer by the California Proposition 65 program (OEHHA, 2021a). In addition, the National Toxicology Program (NTP) listed 1-BP in the 13th Report on Carcinogens, which identifies substances that either are known to be human carcinogens or are reasonably anticipated to be human carcinogens, and to which a significant number of persons residing in the United States are exposed (NTP, 2013). 1-BP is also listed by the International Agency for Research on Cancer (IARC) as a Group 2B

carcinogen, i.e., possibly carcinogenic to humans (IARC, 2018). As of February 4, 2022, US EPA (US EPA, 2022) amended the list of Hazardous Air Pollutants (HAPs) under the Clean Air Act to add 1-BP.

1-BP is promoted as an alternative to ozone-depleting chlorofluorocarbons. Exposure to 1-BP may occur from emissions of facilities or commercial businesses where 1-BP is used as a solvent vehicle for spray and brush-applied adhesives in laminates and foam products, or as a degreasing/cleaning agent for metals, metal products, plastics, optics, and electronics (TRI, 2015; US EPA, 2020a; Louis *et al.*, 2021). 1-BP is also listed in California for limited use in dry cleaning technologies, in which it is used as an alternative solvent in modified perchloroethylene dry-cleaning machines (CARB, 2015). Other applications may include use as a chemical intermediate in the production of agricultural chemicals and basic organic and inorganic chemicals, use in extraction of asphalt, use in coin and scissors cleaning, and commercial/consumer spot cleaning of fabrics (US EPA, 2017a). In California, reduction in chlorinated hydrocarbon use due to phase-out of these compounds has led to the adoption of alternative solvent formulations, such as those including 1-BP, by end-users. No California surveys examining statewide ambient exposure to 1-BP could be found in the literature. A periodic California survey of businesses that conduct solvent cleaning operations noted no use of 1-BP until 2008 (CARB, 2011). In that year, the Statewide Emission Inventory reported a total of 160.7 tons 1-BP emitted due to solvent cleaning operations.

1-BROMOPROPANE

CAS No: 106-94-5



I. PHYSICAL AND CHEMICAL PROPERTIES

(PubChem, 2020)

Molecular formula	C_3H_7Br
Molecular weight	122.99 g/mol
Synonym	n-Propyl bromide
Description	Colorless liquid when fresh
Density/Specific gravity	1.353 @ 20°C/20°C
Boiling point	71°C at 760 mm Hg (torr)
Vapor pressure	110.8 mm Hg (torr) @ 20°C
Solubility	Soluble in acetone, ethanol, ether, benzene, chloroform, carbon tetrachloride; slightly soluble in water (2,450 mg/L @ 20°C)
Conversion factor	1 ppm = 5.03 mg/m^3

II. HEALTH ASSESSMENT VALUES

Unit Risk Factor:	3.7×10^{-6} (μg/m^3)$^{-1}$
Inhalation Slope Factor:	1.3×10^{-2} (mg/kg-day)$^{-1}$

III. CARCINOGENICITY

Carcinogenicity studies for 1-BP have been conducted in rats and mice. There are no human carcinogenicity data.

<u>NTP Cancer Bioassay</u>

The NTP conducted two-year 1-BP inhalation studies in male and female F344/N rats and B6C3F$_1$/N mice (Morgan *et al.*, 2011; NTP, 2011). 1-BP was chosen for study by NTP due to the potential for increasing widespread use and the lack of carcinogenicity data. Rodents were exposed whole-body in chambers to 0, 62.5 (mice only), 125, 250, or 500 (rats only) ppm (314, 629, 1,258 and 2,515 mg/m^3) 1-BP for 6.17 hours/day, 5 days/week for 105 weeks. The daily exposures included the 6 hour exposure time at a uniform vapor concentration plus the ramp-up time of

10 minutes (0.17 hours/day) to achieve 90% of the target concentration after the beginning of vapor generation. The decay time to 10% of the target concentration at the end of the exposures was about 10-11 minutes. A small particle detector was used in the exposure chambers to ensure that 1-BP vapor, and not aerosol, was produced.

The statistically significant ($p < 0.05$) or biologically noteworthy tumor incidences are shown in Table 1 for male and female rats, and in Table 2 for male and female mice. The Cochran-Armitage trend test was used to determine if tumors in all dose groups overall increase as dose increases. Pairwise comparison was performed using the Fisher exact test to determine if tumor incidence in each dose group is increased over that of the control group. Both tests are recommended for carcinogen risk assessment (US EPA, 2005; NTP, 2011).

The rationale and guidelines for combining certain neoplasms and sites is discussed in Brix *et al*. (2010) and McConnell *et al*. (1986). This guidance is used by US EPA (2005) and OEHHA (2009) for carcinogen risk assessment. The recommendation is that benign and malignant neoplasms of the same cell origin (e.g., benign and malignant pancreatic islet tumors) be analyzed both separately and in combination. Likewise, neoplasms with the same histogenesis but showing different morphologic and cellular features (e,g, skin tumors of epithelial origin) should also be analyzed both separately and in combination.

The issue of multiple comparisons resulting in an increased false-positive or Type 1 error rate was also considered. For animal bioassay experiments such as NTP studies that examine both sexes of two species across multiple tumor types, presenting a single significantly increased tumor incidence rate that falls short of the 1% significance level ($p = 0.01$) for common tumors, and 5% significance level ($p = 0.05$) for rare tumors, should be treated with caution (Haseman, 1983; 1990; US EPA, 2005). This is because individual significance levels may correspond to an increased significance level for the experiment considered as a whole. For the tumors in Tables 1 and 2 that presented some or clear evidence of carcinogenicity for 1-BP (i.e., all skin tumors combined in male rats, large intestine tumors in female rats (a rare tumor), and lung tumors in female mice), the significance levels are below these levels described above for common tumors (1% significance level) and rare tumors (5% significance level). These tumor incidence rates in 1-BP-treated animals should be high enough to keep the overall experiment-wise Type 1 error rate constrained to an acceptable level.

F344/N rats

Body weights of male and female rats at all exposure levels were similar to controls, remaining within 8% of controls throughout the 2-year study. Survival was significantly reduced in the 500 ppm males compared to controls (p = 0.033, life table pairwise comparison) (NTP, 2011). In this exposure group, 9 of 37 deaths prior to terminal sacrifice were attributed to chronic inflammation in various organs (lung, nose, skin, and bone) that were related to 1-BP exposure, while the remaining early deaths were attributed to various types of neoplasia that were not treatment-related. In females, decreased survival in the 500 ppm group was not significant (p = 0.054) compared to the controls. However, the life table trend test indicated decreased survival of the female rats with increasing dose (p = 0.028).

Following exposure to 1-BP, the incidence of adenoma of the large intestine (colon or rectum) was significantly increased in 500 ppm female rats and a significant positive trend (p = 0.004) for this tumor was observed. In 1-BP treated males, the low incidence of these tumors (two in the 250 ppm group, and one in the 500 ppm group) resulted in no significant difference relative to controls, and no significant positive trend was found. This tumor is rare in F344/N rats. The historical incidence in 2-year inhalation studies with male rat chamber controls is: 0/349; all routes 2/1,398 (0.1% ± 0.5%), range 0-2%. The incidence of adenoma of the large intestine was exceeded in 250 ppm males (2/50, 4%). The NTP (2011) concluded that the presence of these tumors in exposed females and the low historical incidence in untreated males indicated that the three large intestine tumors found in 1-BP-exposed males were due to 1-BP exposure. Although no carcinomas of the large intestine were found in the 1-BP-exposed rats, adenoma of the large intestine can progress to carcinoma (NTP, 2011a).

Skin tumors of epithelial origin were increased in exposed male rats (Table 1). The tumor incidence of keratoacanthoma was significantly increased in the 250 and 500 ppm groups compared to controls, and a significant positive trend was observed. The tumor incidence of keratoacanthoma or squamous cell carcinoma combined was significantly increased in 500 ppm males and a significant positive trend was observed. Keratoacanthoma is a rapidly growing benign neoplasm of squamous epithelial origin that is considered to progress to squamous cell carcinoma. The historical control range for keratoacanthoma and keratoacanthoma or squamous cell carcinoma (combined) was exceeded in 250 and 500 ppm males. The incidence of basal cell adenoma and squamous cell carcinoma at 250 ppm and 500 ppm, respectively, were not significantly increased, but they exceeded the respective historical control ranges for inhalation studies (Table 1).

When combining all neoplasms of epithelial origin, the tumor incidence of keratoacanthoma, basal cell adenoma, basal cell carcinoma, or squamous cell carcinoma in males was significantly increased in all exposed groups, and a positive trend was observed (Table 1). The incidence for all epithelial tumors combined in all exposed groups exceeded the historical control range for inhalation studies. The NTP (2011) concluded that the increased incidences of all tumors of epithelial origin were a result of 1-BP exposure.

Tumors of the skin were not as prevalent in exposed female rats. A positive trend for tumor incidence was found when squamous cell papilloma, keratoacanthoma, basal cell adenoma, or basal cell carcinoma were combined, but pairwise comparison of 1-BP exposed groups with controls did not result in a significant increase in tumors in any group (Table 1). The tumor incidence in the 500 ppm group did exceed the historical incidence for controls for inhalation studies (2/350 – 0.6% ± 1.0%, range 0-2%) and for all routes of exposure (16/1350 – 1.2% ± 1.8%, range 0-6%). The NTP (2011) concluded there was equivocal evidence for these skin tumors in exposed female rats due to the absence of statistically significant pairwise comparisons for keratoacanthoma alone and for all tumors combined, and because there were no observed squamous cell carcinomas.

A positive trend for the incidence of malignant mesothelioma was observed in male rats, and the incidence in the 500 ppm group was near statistical significance ($p = 0.059$). This neoplasm originated in the epididymis but was also found in other tissues, particularly the testis. The NTP (2011) noted that the historical control incidence was surpassed in the 500 ppm group (inhalation studies: 5/349 – 1.4% ± 2.2%, range 0-6%; all routes: 35/1,398 – 2.5% ± 2.3%, range 0-6%). The NTP concluded there was only equivocal evidence for carcinogenicity for this tumor due to its common occurrence in this strain of male rats, lack of a statistically significant increase in exposed groups relative to controls, and because the 500 ppm group tumor incidence was barely above the historical control range.

In male rats, a significant increase in the tumor incidence for pancreatic islet cell adenoma occurred in most 1-BP-exposed groups, and a positive trend near statistical significance ($p = 0.056$) was observed (Table 1). However, the historical control range for this neoplasm in inhalation studies (0% to 12%) was not exceeded in any of the exposed groups and the mean incidence in historical control inhalation studies (5.7% ± 3.9%) was greater than that in chamber controls (0%). Thus, the NTP considered the increased incidence of this tumor as equivocal evidence for carcinogenicity. No significant difference from control was observed for the incidence of pancreatic islet cell carcinoma, and no positive trend was observed. The incidence of carcinomas in the 125 ppm group (7/50) was above the historical control range

(inhalation studies: 17/349 – 4.9% ± 3.3%, range 2-10%; all routes: 29/1,394 – 2.1% ± 2.6%, range 0-10%). The NTP (2011) concluded that pancreatic islet cell carcinoma demonstrated equivocal evidence of carcinogenicity due to the lack of a significant increase over control incidence.

For pancreatic islet cell adenoma or carcinoma (combined), there was a significantly increased tumor incidence in the 125 ppm group, but a significant positive trend was not demonstrated. The historical control range in the 125 ppm group was exceeded (inhalation studies: 37/349 – 10.6% ± 4.8%, range 6-18%; all routes: 119/1,394 – 8.6% ± 4.0%, range 0-18%). Although not specifically addressed by the NTP, the combined tumor incidence data was apparently not strong enough to affect the conclusion of equivocal evidence for carcinogenicity based on the individual adenoma and carcinoma incidence rates.

The unadjusted tumor incidence data in Table 1 is converted to “effective tumor incidence” (See Section 5 and Tables 5a), which is used to estimate the cancer potency of 1-BP. The description of the effective tumor incidence is provided in Section 5.

Table 1. Unadjusted tumor incidence in rats exposed to 1-BP for two years (NTP, 2011a)[a,b]

Sex and Species	Tumor Type	Incidence by concentration				Statistical p-values for pairwise comparison with controls			
		0 ppm, 0 mg/m^3	125 ppm, 629 mg/m^3	250 ppm, 1258 mg/m^3	500 ppm, 2515 mg/m^3	Trend[c]	125 ppm, 629 mg/m^3	250 ppm, 1258 mg/m^3	500 ppm, 2515 mg/m^3
Male Rats	Large Intestine (colon or rectum): Adenoma	0/50	0/50	2/50	1/50	0.140	1.000	0.247	0.500
	Skin: Basal Cell Adenoma	0/50	1/50	2/50	1/50	0.247	0.500	0.247	0.500
	Skin: Basal Cell Carcinoma	0/50	2/50	1/50	2/50	0.160	0.247	0.500	0.247
	Skin: Keratoacanthoma	0/50	3/50	6/50*	6/50*	0.010	0.309	0.013	0.013
	Skin: Squamous Cell Carcinoma	1/50	1/50	0/50	2/50	0.247	0.753	1.000	0.500
	Skin: Keratoacanthoma or Squamous Cell Carcinoma	1/50	4/50	6/50	8/50*	0.008	0.181	0.056	0.015
	Skin: Keratoacanthoma, Basal Cell Adenoma, Basal Cell Carcinoma, or Squamous Cell Carcinoma	1/50	7/50*	9/50**	10/50**	0.007	0.030	0.008	0.004
	Malignant Mesothelioma	0/50	2/50	2/50	4/50	0.026	0.247	0.247	0.059
	Pancreatic Islets: Adenoma	0/50	5/50*	4/50	5/50*	0.056	0.028	0.059	0.028
	Pancreatic Islets: Carcinoma	3/50	7/50	5/50	3/50	0.662	0.159	0.357	0.661
	Pancreatic Islets: Adenoma or Carcinoma	3/50	10/50*	9/50	8/50	0.158	0.036	0.061	0.100
Female Rats	Large Intestine (colon or rectum): Adenoma	0/50	1/50	2/50	5/50*	0.004	0.500	0.247	0.028
	Skin: Squamous Cell Papilloma, Keratoacanthoma, Basal Cell Adenoma, or Basal Cell Carcinoma	1/50	1/50	1/50	4/50	0.040	0.753	0.753	0.181

(a) The numerator represents the number of tumor-bearing animals; the denominator represents animals examined.

(b) * = p<0.05, ** = p<0.01; p-value indicators are from pairwise comparisons with controls using Fisher exact tests performed by OEHHA

(c) p-values in the trend column are for the Cochran-Armitage trend test performed by OEHHA using BMD software (US EPA, 2017b).

= Tumor type and incidence data represents equivocal finding for carcinogenicity by NTP (2011a)

Nonneoplastic findings included increased incidence of various upper respiratory lesions in the nose, larynx and trachea in some or all exposed groups of rats, including chronic active inflammation, suppurative chronic inflammation, epithelial hyperplasia in the nose and trachea, and respiratory metaplasia of the nasal olfactory epithelium. Chronic suppurative inflammation was significantly increased in the lung of 500 ppm females. Chronic suppurative inflammation was also present in skin and some other tissues of 500 ppm males and females. These lesions are characterized by the presence of Splendore Hoeppli material, which were not seen in controls. The presence of Splendore Hoeppli material has been associated with diseases that compromise the immune system (NTP, 2011a).

B6C3F1/N mice

Body weights of male and female mice at all exposure levels were similar to controls throughout the 2-year studies (NTP, 2011). Survival of the mice was unaffected by 1-BP exposure.

There was no evidence of carcinogenic activity of 1-BP in male mice. However, an increased incidence of lung tumors was observed in 1-BP-exposed female mice (Table 2). The rationale for analyzing benign and malignant neoplasms of alveolar/bronchiolar lung tissue, both separately and in combination, is discussed in Brix *et al.* (2010) and McConnell *et al*. (1986). Principally, benign alveolar/bronchiolar tumors may progress to malignant alveolar/bronchiolar tumors, and a statistically significant increase in tumor incidence may be achieved by combining these neoplasms. Significantly increased tumor incidences of alveolar/bronchiolar adenomas (250 ppm group), alveolar/bronchiolar carcinomas (62.5 and 125 ppm groups), and combined alveolar/bronchiolar adenoma or carcinoma (all exposed groups) were present, including positive trends for the adenoma and combined adenoma or carcinoma. In addition, multiple adenomas were found in two 250 ppm females and multiple carcinomas were found in two 62.5 ppm females, one 125 ppm female, and one 250 ppm female. The inhalation study historical control range for alveolar/bronchiolar adenoma and for the adenoma or carcinoma (combined) was exceeded by the 250 ppm group and by all exposed groups, respectively.

The unadjusted tumor incidence data in Table 2 are converted to “effective tumor incidence” (See Section 5 and Table 5b), which is used to estimate the cancer potency of 1-BP. The description of the effective tumor incidence is provided in Section 5.

Table 2. Un-adjusted tumor incidence in mice exposed to 1-BP for two years (NTP, 2011a)[a,b]

Sex and Species	Tumor Type	Incidence by concentration				Statistical p-values for pairwise comparison with controls			
		0 ppm, 0 mg/m^3	62.5 ppm, 314 mg/m^3	125 ppm, 629 mg/m^3	250 ppm, 1258 mg/m^3	Trend[c]	62.5 ppm, 314 mg/m^3	125 ppm, 629 mg/m^3	250 ppm, 1258 mg/m^3
Female Mice	Lung: Alveolar/Bronchiolar Adenoma	1/50	6/50	4/50	10/50**	0.004	0.056	0.181	0.004
	Lung: Alveolar/Bronchiolar Carcinoma	0/50	7/50**	5/50*	4/50	0.189	0.006	0.028	0.059
	Lung: Alveolar/Bronchiolar Adenoma or Carcinoma	1/50	9/50**	8/50*	14/50**	<0.001	0.008	0.015	<0.001

(a) The numerator represents the number of tumor-bearing animals; the denominator represents animals examined

(b) * = $p<0.05$, ** = $p<0.01$; *p*-value indicators are from pairwise comparisons with controls using Fisher exact tests performed by OEHHA;

(c) p-values in the trend column are for the Cochran-Armitage trend test performed by OEHHA using BMD software (US EPA, 2017b).

Increased incidences of nonneoplastic findings were observed in the upper and lower respiratory airways in some or all exposed groups of mice. Bronchiolar regeneration was observed in most exposed male and female mice. This lesion was almost completely absent in control mice. Cytoplasmic vacuolization in the bronchiolar epithelium of the lung, the respiratory epithelium of the nose, and the epithelium of the larynx and trachea was increased in all exposed male groups. Cytoplasmic vacuolization was also increased in upper and lower airways in all exposed female groups, but at lower rates compared to males. In the nose of male and female mice, there was also an increased incidence of hyperplasia of the respiratory epithelium and metaplasia of the olfactory epithelium in some or all exposed groups.

Toxicokinetics

The mechanism by which 1-BP causes cancer has not been elucidated, although metabolic activation to reactive metabolites is suspected to be involved (Morgan *et al.*, 2011). The metabolism of inhaled and absorbed 1-BP occurs primarily through oxidative metabolism via P450 enzymes, conjugation with glutathione (GSH) and debromination, although the majority of 1-BP can be excreted unchanged in exhaled air. Metabolism of 1-BP has been shown to produce effects that other carcinogens are known for, such as oxidative stress via glutathione depletion and immunomodulation (Lee *et al.*, 2007; Guyton *et al.*, 2009; Liu *et al.*, 2009; Miao *et al.*, 2018; Yang *et al.*, 2021).

Rodent models

Toxicokinetic studies have been carried out in male F344 rats and B6C3F$_1$ mice (Garner *et al.*, 2006). The disposition of [1-^{14}C]-1-BP radioactivity following relatively low doses (3.4 - 5.9 mg/kg) via intravenous (IV) administration was similar in rats and mice. A majority of the radiolabel was exhaled as volatile organic compounds (VOC; 40–71%) or as $^{14}CO_2$ (10–31%) within four hours following administration. The radiolabel recovered in urine ranged from 17 to 23%. Roughly 2% and 6% was recovered in feces and carcass, respectively. The radiolabel exhaled as VOC was later identified in Garner et al. (2015) as the parent compound, 1-BP.

The identification of urinary metabolites was carried out following IV administration and inhalation exposure of [1,2,3-^{13}C]-labeled 1-BP in rats (Garner *et al.*, 2006). Similar to the inhalation route, IV administration does not involve hepatic “first pass” metabolism and is more likely to be consistent with metabolism derived from workplace or environment inhalation. As expected, similar results were obtained for both exposure routes. The main urinary metabolites and percent of the total excreted in the urine were: *N*-acetyl-*S*-propylcysteine (37%), *N*-acetyl-3-(propylsulfinyl)alanine

(5%), *N*-acetyl-*S*-(2-hyroxypropyl)cysteine (16%), 1-bromo-2-hydroxypropane-*O*-glucuronide (9%), *N*-acetyl-*S*-(2-oxopropyl)cysteine (12%), and *N*-acetyl-3-[(2-oxopropyl)sulfinyl]alanine (% not stated). The authors indicated that many of these metabolites were likely formed after cytochrome P450 (CYP)-catalyzed oxidation of 1-BP to 1-bromo-2-propanol and bromoacetone, followed by GSH conjugation with either of those metabolites. Other identified 1-BP metabolites formed by CYP-mediated oxidation in rodents include α-bromohydrin and glycidol, both of which have been shown to be mutagenic (Stolzenberg and Hine, 1979; IARC, 2000; Ishidao *et al.*, 2002; Garner *et al.*, 2007). The scheme established in Garner et al. (2015) for 1-BP metabolism in the rat is shown in Figure 1.



Figure 1. Metabolism of 1-BP in rats: Figure 2 of Garner et al. (2015).
* = debromination step; GST = glutathione-S-transferase; FCM = flavin monooxygenase; Vmax = maximal velocity; Km = Michaelis Constant; Kgst = proportionality constant for linear pathway metabolized by glutathione transferase; →→ multiple steps of reaction

When rats were pretreated with 1-aminobenzotriazole, a potent but nonselective CYP inhibitor/inactivator, the only urinary metabolite found was *N*-acetyl-*S*-propylcysteine, which contributed greater than 90% of the urinary radioactivity (Garner *et al.*, 2006). This metabolite is formed by direct conjugation of 1-BP with GSH. The authors concluded that CYP enzymes contribute significantly to the production of the major oxidative metabolites of 1-BP.

In a follow-up study, Garner et al. (2007) exposed *Cyp2e1*$^{-/-}$ and wild-type (WT) mice to [1,2,3-^{13}C]-1-BP to determine the contribution of cytochrome P450 2E1 (CYP2E1) to the metabolism and elimination of the chemical. In *Cyp2e1*$^{-/-}$ mice, which lack the CYP2E1 isozyme, the elimination half-life in gas uptake studies was longer compared to WT mice (3.2 vs. 1.3 hours). The major urinary metabolite, *N*-acetyl-*S*-(2-hydroxypropyl)cysteine, which is derived largely though oxidative metabolism, was reduced about 50% in *Cyp2e1*$^{-/-}$ mice compared to WT mice. In addition, the ratio of products of direct conjugation of 1-BP with GSH to oxidative 2-hydroxylation increased 5-fold in *Cyp2e1*$^{-/-}$ mice relative to WT mice. These data suggested to the authors that CYP2E1 is a major CYP contributor in the oxidative metabolism of 1-BP.

Garner and Yu (2014) evaluated the species and sex-dependent factors influencing 1-BP toxicokinetics in F-344 rats and B6C3F$_1$ mice after intravenous and inhalation exposure. Male F-344 rats were given intravenous (iv) bolus injections of 1-BP at 5 or 20 mg/kg body weight (BW), and blood levels were determined at time intervals up to 4 hours. Male and female F-344 rats and B6C3F1 mice were also exposed to initial inhalation concentrations of 70, 240, 800, and 2,700 ppm (0, 350, 1,200, 4,000, and 14,000 mg/m^3) 1-BP in a closed gas uptake system, and subsequent 1-BP atmospheric loss rates monitored for 6 hours. Systemic clearance of bolus iv-administered 1-BP in the blood of rats was rapid and decreased with increasing dose. Approximately 99% was eliminated from the body by 3 hours post-exposure. The average elimination half-life was 0.39 ± 0.08 and 0.85 ± 0.09 hour at 5 and 20 mg/kg BW, respectively. However, systemic clearance decreased with increasing iv dose. Plasma bromine levels were measured in the rats after iv administration; bromine is released from 1-BP either by oxidative metabolism or by conjugation with GSH. The bromine levels suggested that approximately 30% of administered 1-BP was metabolized by either route and eliminated in urine. The authors surmised that the remainder was largely lost by exhalation, either as 1-BP or as CO_2.

In the gas uptake portion of the study, as the air concentration of 1-BP increased, the terminal air elimination rate decreased suggesting to the authors that one or more routes of elimination became saturated as chamber concentration increased (Garner and Yu, 2014). At a given starting concentration, male rats tended to eliminate 1-BP from the chamber more rapidly than females. Plasma bromide levels were also

measured in the rats following gas uptake. The results showed that oxidative metabolism in female rats was lower compared to males, indicating that oxidative metabolism in females may be saturated at lower concentrations. In male and female mice, elimination of inhaled 1-BP occurred at similar rates up to 800 ppm. At higher concentrations, the half-life increased, with male mice eliminating 1-BP from the chamber more slowly than female mice. The data also showed that mice tend to have a higher 1-BP oxidative metabolic capacity relative to rats. Regarding urinary metabolites, the authors noted that rats produced both directly GSH-conjugated parent and oxidative metabolites, while mice only produced a single oxidative metabolite (2-hydroxybromopropane) which was then conjugated with GSH.

Rats were also pretreated with chemical inhibitors of CYP (1-aminobenzotriazole) and GSH (D,L-buthionine (S, R)-sulfoximine) synthesis, prior to exposure to 1-BP at 800 ppm (4,024 mg/m^3) in inhalation chambers (Garner and Yu, 2014). The half-life of 1-BP in rats following inhibition of CYP (9.6 hours) or depletion of GSH (4.1 hours) increased relative to controls (2.0 hours), supporting the authors' position that 1-BP elimination is highly dependent on both CYP and GSH-dependent metabolism.

Applying the above gas-uptake experiments in the Fischer 344 rat, a physiologically based pharmacokinetic (PBPK) model was developed by simulating the 1-BP level in a closed chamber (Garner *et al.*, 2015). They tested the hypothesis that metabolism includes both P450 CYP2E1 activity and GSH conjugation. The results showed that two metabolic pathways adequately simulated 1-BP levels in the closed chamber. Furthermore, the model was tested by simulating the gas-uptake data of the female rats pretreated with the P450 inhibitor 1-aminobenzotriazole, or the GSH synthesis inhibitor d,l-buthionine (S,R)-sulfoximine, prior to inhalation of 800 ppm (4,000 mg/m^3) 1-BP. As in their previous study, pretreatment with either of these inhibitors dramatically prolonged the half-life of 1-BP elimination, and suggested CYP 450 and GSH had major roles for 1-BP metabolism.

Based on the closed chamber and gas-uptake data in the female rat, sex-specific metabolic parameters were also estimated and extrapolated into different exposure levels in the PBPK model (Garner et al., 2015). In the model, the metabolic rate Vmax and Km were about 1.5 and 2 times larger in the male rat than those in the female. The GSH-related constant (Kgst) in the male rat was estimated to be about 2 times that of the female constant. After adjusting Vmax by the rat's body weight (male rat body weight was considerably greater than the female rat body weight), the values were improved and shown to be similar between male and female rats, which indicates body weight as a possible contributor to the sex-specific differences in the toxicokinetics of 1-BP.

A human PBPK model for 1-BP was developed by extrapolating the metabolic parameters obtained from the gas-uptake studies in rats, and applying them to a general human PBPK model for volatile compounds (Garner et al., 2015). In a repeated exposure scenario (20 or 200 ppm per day), modeling showed that rats do not accumulate 1-BP in blood, whereas humans show a 20% increase over 5 days of exposure. While 1-BP has a moderate fat:blood partition coefficient (20.2), a higher fat tissue content in humans (21.4%) compared to rats (7%) may explain this increase. However, additional experimental data for specific organ dosimetry and for the metabolites of 1-BP will need to be incorporated into the PBPK model to allow the quantitative extrapolation of animal studies to humans for risk assessment purposes.

Toxicokinetics in children and adults

The urinary mercapturic metabolite, N-acetyl-*S*-propylcysteine, found in rodents by Garner and associates has also been identified in the urine of 1-BP-exposed workers (Valentine *et al.*, 2007; Hanley *et al.*, 2009). In addition, a urinary metabolite not identified in rodents, N-acetyl-S-(3-hydroxy-n-propyl)cysteine, has been found in workers exposed to 1-BP (Cheever *et al.*, 2009; Hanley *et al.*, 2009). As in rodents, N-acetyl-*S*-propylcysteine was identified as the predominant urinary metabolite in exposed workers and was proposed as a biomarker of exposure. Urinary bromide has also been proposed as a biomarker of 1-BP exposure in workers (Hanley *et al.*, 2010). Bromide analysis in urine, however, may not be as ideal for evaluating low level occupational and non-occupational exposure to 1-BP due to background interference from dietary sources of bromide, such as seafood. Hanley *et al*. (2010) estimated that the lowest 1-BP TWA level above which urinary bromide is a valid biomarker of 1-BP exposure is approximately between 0.5 and 1.0 ppm.

In peer-reviewed reports, NIOSH investigators examined the association between airborne 1-BP exposure and 1-BP urinary metabolites in 30 workers from two factories that manufacture polyurethane foam seat cushions using a spray adhesive containing 1-BP (Hanley *et al.*, 2006; Hanley *et al.*, 2009; Mathias *et al.*, 2012). Time-weighted average (TWA) geometric mean breathing zone concentrations of 1-BP were 92.4 ppm (460 mg/m^3) for sprayers (n = 13) and 10.5 ppm (53 mg/m^3) for non-spraying jobs (n = 17). The urine was collected into composite samples for three daily time intervals over two days starting on Monday: at work, after work but before bedtime, and upon awakening. In addition, seven spot urine control samples were collected from persons not employed at the factories. Urinary N-acetyl-S-propylcysteine in urine showed the same trend as TWA exposures to 1-BP (i.e., sprayers had higher levels). Geometric mean 24- and 48-hour total excretion levels for N-acetyl-S-propylcysteine were 36.8 and 43.9 mg/L for sprayers, respectively, and 7.97 and 9.68 mg/L for non-sprayers, respectively. Associations of N-acetyl-S-

propylcysteine concentrations with 1-BP TWA exposure were statistically significant for both sprayers ($p < 0.05$) and non-sprayers ($p < 0.01$). The geometric mean excretion level for controls was 0.035 mg/L, two to three orders of magnitude less than that of the factory workers. The study confirmed that urinary N-acetyl-S-propylcysteine is an important 1-BP metabolite and an effective biomarker for highly exposed foam cushion workers.

The unmetabolized parent compound has also been identified in end-of-shift urine samples from 1-BP-exposed production workers, and was significantly correlated to the concentration of 1-BP in air (Kawai *et al.*, 2001; Ichihara *et al.*, 2004a). Measurable levels of 1-BP in end-of-shift urine was found when the TWA exposure was >2 ppm (Kawai *et al.*, 2001). Unmetabolized 1-BP has not been detected in the urine of rats and mice (Garner *et al.*, 2006). Due to potential evaporative loss of 1-BP from urine, the samples need to be immediately placed in sealed head-space vials with analysis often conducted the next day (Ikeda, 1999; Kawai *et al.*, 2001).

CYP2E1 is known to be a major CYP isozyme that metabolizes 1-BP in rodents. Initial reports in humans did not detect CYP2E1 in fetal liver samples, but CYP2E1 increased rapidly within hours of birth (Vieira *et al.*, 1996; Cresteil, 1998). A more recent report with 73 fetal samples and 165 postnatal samples found that CYP2E1 is detectable by immunological techniques at low levels in some (37%) fetuses beginning in the second trimester, and in the third trimester it is present in most (80%) fetuses at 10-20% of adult levels (Johnsrud *et al.*, 2003; Hines, 2007). In the neonatal period (0-29 days) the mean level was about 25% that of adults but the variability among samples was nearly 80-fold (Johnsrud *et al.*, 2003). From 1 month to 1 year, the mRNA for CYP2E1 accumulates and CYP2E1 protein increases toward adult levels (Table 3) (Vieira *et al.*, 1996; Hines, 2007) (Vieira *et al.*, 1996; Hines, 2007). However, considerable interindividual variability is observed in the immediate postnatal (1–6 months) onset or increase in expression of CYP2EI and other CYP enzymes (Johnsrud *et al.*, 2003; Hines, 2007).

Table 3. Increase of CYP2E1 (mean ± SD) with age in human liver (Hines, 2007)

Age	n	pmol CYP2E1/mg protein
1st trimester fetus: 8-13.4 weeks	14	- (not detectable)
2nd trimester fetus: 13.6-25 weeks	45	0.3 ± 0.6
3rd trimester fetus: 27-40 weeks	14	5.8 ± 4.6
Neonate: 0-29 days	42	13.4 ± 16.0
Infant: 1.1-11.3 months	64	36.2 ± 20.3
Prepubertal: 1.1-10.0 years	41	43.1 ± 20.6
Adolescent: 11.0-17.7 years	20	~68[a]
Adult	-	~50[a]

[a] Median, in pmol CYP2E1/mg protein

OEHHA noted that low levels of CYP2E1 in infants may reduce metabolism of 1-BP in the infant, leading to possible increased elimination of unchanged 1-BP via exhalation. Presuming that the parent compound has little or no toxicity, this could decrease, rather than increase, the sensitivity of the very young to the toxicity of 1-BP. However, there is currently no evidence to support this concept.

In non-occupational settings, surveys of children and pregnant women have found the 1-BP metabolite, N-acetyl-S-propylcysteine in most urine samples examined. From 2009 to 2010 the National Children's Vanguard Study collected urine samples from 488 third trimester pregnant women at in-person study visits (Boyle *et al.*, 2016). Urinary metabolites of 28 VOCs were quantified simultaneously using ultra-high performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry (UPLC-ESI/MSMS). N-acetyl-S-propylcysteine was present in 99% of the urine samples. The levels reported were 2.61 ng/mL for the 50th percentile, 9.44 ng/mL for the 75th percentile, and 4,260 ng/mL for the maximum person. The authors did not identify sources of the metabolite, other than to note that dry cleaning and metal cleaning solvents are known sources of 1-BP.

Data from the National Health and Nutrition Examination Survey (NHANES) for 2011-2012 were used to evaluate variability in the levels of 20 urinary metabolites of VOCs (including 1-BP) by age, gender, and race/ethnicity (Jain, 2015). Although it is not associated with smoking, NHANES included N-acetyl-S-propylcysteine in its list of 28 VOC metabolites based on its similarity in chemistry to tobacco metabolites. Among 417 children ages 6 through 11, the mean levels of N-acetyl-S-propylcysteine were 2.6 (2–3.3) ng/mL in boys and 3.3 (2.5–4.3) ng/mL in girls (adjusted geometric means with 95% confidence intervals). Jain also reported that concentrations of the urinary 1-BP metabolite decreased with the increase in the number of rooms in the child's home ($p = 0.03$). The number of rooms in a child's home is an indicator of socioeconomic status. However, the reason for this correlation was not known. No correlation of the 1-BP metabolite was observed with age, poverty income ratio, body mass index, or number of smokers in the house.

More recently, Louis *et al.* (2021) examined urinary VOC biomarker concentrations among a representative sample of U.S. women (n = 3,278) that participated in NHANES 2015-2016. For the 1-BP metabolite N-acetyl-S-propylcysteine, the detection frequency was 81% in the urine samples, and the geometric mean was 4.04 ng/mL. These values were compared to a cohort of hairdressers (n = 23) working in salons that primarily serve women of color. For the urinary metabolite N-acetyl-S-propylcysteine the detection frequency was 91%, and the geometric mean was more than 4 times higher (15.1 ng/mL) compared to U.S. women. The source of hairdresser exposure was 1-BP in scissor lubricant.

These surveys suggest potential widespread, low-level non-occupational exposure to 1-BP, but no studies could be found that investigated 1-BP exposure and sources of exposure within the general population. Products that contain 1-BP appear to be mostly intended for industrial and commercial uses (US EPA, 2017a; 2020a). However, many products containing 1-BP may be available for consumer use and can be purchased on the internet or off the shelf (US EPA, 2017a; Yang, 2020). These products include aerosol spray adhesives, aerosol spot removers, aerosol cleaners and degreasers, coin and scissors cleaning, adhesive accelerant used in arts, crafts and hobby materials, automotive care products such as refrigerant flush, cutting oils, and anti-adhesive agents used in mold cleaning and release products. These findings suggest some exposure to 1-BP occur from products that consumers can obtain.

The population studies also observed that geometric mean concentrations of urinary N-acetyl-S-propylcysteine among the general population of about 2 to 4 ng/ml, or 0.002 to 0.004 mg/L. Compared to 1-BP worker exposure studies (Hanley *et al.*, 2006; Hanley *et al.*, 2009; Mathias *et al.*, 2012) with urinary N-acetyl-S-propylcysteine levels of about 8,000 to 44,000 ng/ml (8 to 44 mg/L), non-occupational exposure is considerably lower. The TWA geometric mean 1-BP concentration from the 1-BP worker studies were 10.5 to 92.4 ppm, which would suggest mean 1-BP levels among participants in the surveys were in the ppb range.

In theory, exposure to VOCs similar in structure to 1-BP, when absorbed and metabolized, may also generate measurable urinary levels of N-acetyl-S-propylcysteine. As a result, US EPA (2020a) suggested that use of the urinary metabolite as a biomarker for the general population was uncertain. However, published reviews of mercapturic acid metabolites indicate that N-acetyl-S-propylcysteine is not a common metabolite, at least among more commonly found air pollutants and halogenated and non-halogenated VOCs used in industry (van Welie *et al.*, 1992; Mathias and B'hymer, 2016; Konkle *et al.*, 2020).

Genotoxicity

The genotoxicity and mutagenicity database for 1-BP is not extensive, and the overall results have been mixed. Genotoxicity studies are summarized below, followed by a table summary (Table 4 at the end of the section).

DNA strand-break tests

The comet assay is a commonly used method to identify DNA lesions (*e.g.*, breaks or alkali-labile sites) following exposure of an isolated cell culture with a genotoxin. This assay measures premutagenic lesions, which, in intact cells, can be removed by

DNA repair processes, if the repair occurs prior to DNA replication. Thus, positive assay data for a given compound do not necessarily indicate that the compound will induce mutations.

Toraason and coworkers used the comet assay to assess DNA damage in human leukocytes exposed *in vitro* to 1-BP, and in peripheral leukocytes *in vivo* from 53 workers occupationally exposed at two facilities to 1-BP (Toraason *et al.*, 2006). In the *in vitro* portion of the study, leukocytes were collected from a single non-1-BP-exposed human volunteer and cultured with 1- or 2-BP (0, 0.01, 0.1 or 1 mM). The cells were cultured without metabolic activation. Both 1- and 2-BP induced a significant increase ($p < 0.05$, ANOVA) in comet tail moment at the highest concentration (1 mM). However, 1-BP induced apoptosis at a lower concentration (0.1 mM), which the authors suggested could mean cells with excessive DNA damage may be eliminated and reduce the potential for mutation.

In the *in vivo* worker study, 1-BP was used at the facilities as a solvent for spray adhesives in foam cushion fabrication (Toraason *et al.*, 2006). Breathing zone samples, collected with personal air monitors, was assessed in sprayers and non-sprayers for 1 to 3 days. The exposure concentrations ranged from 0.2 to 271 ppm (1 to 1,363 mg/m^3). The mean 1-BP time-weighted average (TWA) at Facility A for sprayers (n = 3 and 10 for men and women, respectively) and non-sprayers (n = 15 and 14 for men and women, respectively) was 83 ± 85 ppm and 2 ± 2 ppm, respectively. The mean 1-BP TWA at Facility B for sprayers (n = 6, women only) and non-sprayers (n = 3 and 13 for men and women, respectively) was 21 ± 5 ppm and 5 ± 1 ppm, respectively. The study lacked a control group with no 1-BP exposure. Internal biomarkers of exposure (serum and urine Br levels) were highly correlated with 1-BP environmental exposure levels.

At both facilities, comet tail moments of leukocytes from sprayers were greater than comet tail moments of leukocytes from non-sprayers, but the difference did not reach statistical significance at $p < 0.05$ (Toraason *et al.*, 2006). An increased dispersion coefficient ($p < 0.05$) in sprayers from Facility A was observed at the end-of-week relative to start-of-week. The dispersion coefficient is the tail moment variance divided by the mean, and variance was determined from 100 leukocytes from each sample. The increased dispersion coefficient during the work week occurred in the subgroup with the highest exposure (i.e., sprayers at Facility A), which suggested to the authors that comets in a sub-population of cells were affected by 1-BP. However, confirming this conclusion would require data indicating that dispersion coefficients were not increased during the week in an unexposed control group, which was not included in this study.

Using multiple linear regression models, Toraason *et al.* found that start-of-week tail moment was significantly associated with serum Br quartiles ($p < 0.05$). End-of-week comet tail moment was also significantly associated with 1-BP TWA quartiles and serum Br quartiles ($p < 0.05$). For quartile analysis, all workers were placed into four exposure groups of equal number, (low, medium low, medium high and high exposure). Other positive associations were observed with tail moment (e.g., 1-BP TWA log ppm, serum Br log mg/dl), but did not reach statistical significance. No statistically significant positive associations were found with the dispersion coefficient and exposure. Overall, the authors found the comet assay results inconsistent, providing only limited evidence that 1-BP increased DNA damage in the workers. Possible confounders cited included temporal variation in the comet assay, lack of breathing zone data from some workers, breathing zone concentrations of 1-BP too low to show definitive *in vivo* evidence of DNA damage in leukocytes, and small sample size.

The human hepatoma cell line, HepG2, was used to determine if 1-BP can induce DNA single strand breaks in these cells *in vitro* (Hasspieler *et al.*, 2006). In addition, cell viability and altered enzyme activity were measured using the neutral red uptake assay and the ethoxyresorufin *O*-deethylase assay, respectively. The tests were performed at 1-BP concentrations of 0, 100, 200, 250, 300, 400, and 500 ppm on HepG2 cells. 1-BP did not induce an increase in single strand breaks at the concentrations tested. Cell viability was reduced at the highest concentration (500 ppm), and no effect on enzyme activity was observed.

DNA Adduct formation in vitro and in vivo

Two studies have demonstrated the formation of N^7-guanine adducts both *in vitro* and *in vivo* following 1-BP exposure (Thapa, 2016; Nepal *et al.*, 2019). N^7-guanine adducts have been shown to be excellent biomarkers for internal exposure to direct-acting and metabolically activated carcinogens (Boysen *et al.*, 2009). However, N^7-guanine adducts themselves generally do not persist, and are not likely to be mutagenic.

Thapa et al., (2016) observed the formation of N^7-guanine adduct (i.e., N-propyl guanine adduct) when 1-BP was incubated with 2'-deoxyguanosine. Subsequently, 1-BP was incubated with calf thymus DNA *in vitro* under physiological conditions for 18 hr, following which unreacted 1-BP was removed and the reactant subjected to thermal hydrolysis to look for the presence of N-propyl guanine. The adduct was found to be generated in a dose-dependent manner without enzymatic support, suggesting that 1-BP could be a direct-alkylating agent.

Adult male Sprague-Dawley rats were injected intraperitoneally with 500 or 1000 mg/kg 1-BP once or daily for three days and then necropsied six hours following the last injection to determine the extent of N-propyl guanine adduct formation in DNA of several organs (Nepal *et al.*, 2019). The highest levels of adduct formation (in pmole/g DNA) was found in the liver, followed by spleen and kidney. Smaller amounts were observed in testis and lung, and none was detected in heart tissue. DNA adduct formation in tissues increased in both a time- and dose-dependent manner.

In a subsequent study by Nepal et al. (2019), 1-BP was incubated *in vitro* with calf thymus DNA, both with and without liver homogenate. Formation of N-propyl guanine was not affected by the addition of liver homogenate, suggesting to the authors that 1-BP can act as a direct alkylating agent.

Induction of DNA repair

In addition to the DNA single strand break test conducted by Hasspieler et al. (2006), the ability of 1-BP to induce DNA repair in human HepG2 hepatoma cells was investigated over the same concentration levels (0, 100, 200, 250, 300, 400, and 500 ppm). Repair of DNA was measured by incorporation of labeled nucleotides ([^{3}H]-thymidine) at previously damaged DNA sites. 1-BP did not induce an increase in DNA repair over the range of concentrations tested.

Bacterial mutation tests

Barber and coworkers were able to show mutagenic activity of 1-BP in the Ames Salmonella test when evaporation of 1-BP was prevented by using a closed system (Barber et al., 1981). The plated bacteria were exposed to 1-BP vapor at concentrations of 1.1, 2.3, 4.9, 9.0, and 20.3 µmoles/plate (135, 283, 603, 1107, and 2497 µg/plate, respectively) for a period of 48 hours. Bacterial strains tested included *Salmonella typhimurium* strains TA1535, TA1537, TA1538, TA98, and TA100. 1-BP was mutagenic only in *S. typhimurium* TA1535 and TA100 strains, showing similar activity in the presence and the absence of induced-rat liver activation enzymes (S9). This finding indicated it is a direct acting mutagen.

The mutagenicity of 1-BP was also tested in the five *S. typhimurium* strains (i.e., TA98, TA100, TA1535, TA1537 and TA1538) and *Escherichia coli* strain WP2 uvrA, with and without S9 mix, by BioReliance (2015). 1-BP concentrations tested were 1.5, 5.0, 15, 50, 150, 500, 1500 and 5000 µg/plate in the initial toxicity-mutation assay, and 50, 150, 500, 1500, 2000, 3000, and 5000 µg/plate in the confirmatory mutagenicity assays. The highest concentration of 5000 µg/plate resulted in cytotoxicity. The study also used a closed system to prevent volatilization of 1-BP,

but consisted of a preincubation step of mixing bacteria with 1-BP liquid in screw cap tubes for 90 minutes, followed by plating and incubation for 48 to 72 hours. Unlike the results of Barber et al. (1981), no evidence of mutagenicity was observed in any strain, with or without S9 mix. This study has not been published in a peer-reviewed publication, but was extensively summarized by U.S. EPA (2020a).

1-BP was not mutagenic in either of two independent bacterial mutagenicity assays, each conducted with and without S9 (NTP, 2011). Bacterial strains tested included *Salmonella typhimurium* strains TA97, TA98, TA100, and TA1535, and *Escherichia coli* strain WP2 *uvrA*/pKM101. 1-BP concentrations tested were 33, 100, 333, 1000, 3333, and 10,000 µg/plate. The NTP (2011) did not use a closed system to prevent potential 1-BP loss due to volatilization, as Barber *et al.* had used. NTP suggested volatility as a possible cause of the negative results in the study. Cytotoxicity occurred at high treatment doses, but it is unclear what the actual exposure levels were to the bacteria.

U.S. EPA (2020a) noted that among the two closed system studies, the BioReliance (2015) study may have had some method limitations that contributed to a negative finding for mutagenicity. The exposure method by Barber et al. (1981) consisted of vapor exposure for 48 hours in a fully enclosed chamber while the BioReliance assay employed screw cap tubes with “minimal” headspace for the 90 minute preincubation step. Analytical concentrations of 1-BP in these preincubation tubes (without metabolic activation) during the confirmatory assays were only 4-37% of target concentrations at the beginning of the preincubation period, and 2-5% of target concentrations by the end of the preincubation period.

Alternatively, the demonstration of cytotoxicity at the highest dose in the two mutagenicity studies with all negative results suggests that the absence of mutagenicity did not result from lack of 1-BP in the test medium, but rather from lack of mutagenic activity of 1-BP.

Mammalian cell gene mutation tests

1-BP was investigated for the ability to induce mutations *in vitro* at the thymidine kinase (TK) locus in L5178Y mouse lymphoma cells (Elf Atochem, 1996). The test determines if a substance can induce forward mutation from the parental type ($TK^{+/-}$) to the mutant form ($TK^{-/-}$), which in a specific medium only allows mutant cells to grow and form colonies. The top dose level of 1-BP used was based on cytotoxicity, identified as ≥10-20% relative survival assessed by relative cloning efficiency. Two independent tests were run, each in the presence or absence of S9 mix, resulting in a total of four tests. A positive response was considered to be a dose-related

increase in mutant frequency and/or a reproducible increase in the mutant frequency (at least a doubling compared to control) for at least one dose level.

Over a dose range of 125 to 1500 µg/ml 1-BP (specific dose levels not provided), without S9 mix, a reproducible and significant increase in the mutation frequency occurred between 1000 and 1500 µg/ml. The relative cloning efficiency at 1500 µg/ml was 21-33%, indicating acceptable viability for the tests. A significant increase in the mutation frequency of both large and small colonies was observed. Small, slow growing colonies are mainly produced by chromosome rearrangements and large colonies are mainly produced by point mutations. With S9 over a 1-BP dose range of 125 to 2500 µg/ml, no increase in mutation frequency was observed in the first test. However, a significant increase in the mutation frequency together with an increase in the number of small colonies was observed at 1500 to 2000 µg/ml in the second test. The relative cloning efficiency at 1500 and 2000 µg/ml was 36 and 9%, respectively.

Under the experimental conditions, the authors concluded that 1-BP showed mutagenic activity in their mouse lymphoma assay, especially without S9 mix. Although this study has not been published in a peer-reviewed publication, the NTP-CERHR expert panel (NTP, 2003) found that this study was well conducted and without any perceived weaknesses. However, OEHHA notes that there is a paucity of data to determine if 1-BP can induce mutations in other mammalian cell assays (e.g., hypoxanthine phosphoribosyl transferase (HPRT) gene mutation assay in Chinese hamster ovary cells or V79 cells).

Chromosomal damage

The frequency of micronucleated cells in mouse bone marrow cells was examined following intraperitoneal (IP) injection of Swiss OFI/ICO:OF1 mice (at least 5 animals/group) to 600 mg/kg (males) or 800 mg/kg (females) 1-BP (Elf Atochem, 1995). Micronuclei are biomarkers of induced structural or numerical chromosomal alterations and are formed when acentric fragments or whole chromosomes fail to incorporate into either of two daughter nuclei during cell division. Initial studies found that exposure of male mice to 800 mg/kg 1-BP by IP injection resulted in mortality, so the dose was reduced to 600 mg/kg for male mice. No increase in micronucleated erythrocytes in bone marrow was observed in either male or female mice. A positive control group treated with cyclophosphamide did show a significant increase in micronucleated erythrocytes. This study has not been published in a peer-reviewed publication, but was summarized by the NTP-CERHR expert panel (NTP, 2003). The panel found the study to be well conducted and without any perceived weaknesses.

Mouse peripheral blood was examined for the frequency of micronucleated erythrocytes following 3-month inhalation exposure of male and female $B6C3F_1$ mice to 62.5, 125, 250, or 500 ppm (314, 629, 1,258, and 2,515 mg/m^3, respectively) 1-BP (NTP, 2011). No increases in the frequencies of micronucleated normochromatic erythrocytes were observed in the 1-BP-exposed mice.

Transgenic rodent mutation assay

A gene mutation study was conducted with 1-BP in Big Blue® transgenic female B6C3F1 mice to investigate the mutagenic mode of action (Stelljes *et al.*, 2019). The assay measures the mutation frequency in the *cII* gene in any tissue in the body. Female transgenic mice (7 per group) were exposed to 1-BP 6 hours/day, 5 days/week, for 28 days at the concentrations used in the NTP (2011) mouse carcinogenicity study – 0, 62.5, 125, and 250 ppm. Another group of female transgenic mice were exposed to N-ethyl-N-nitrosourea, a known mutagen, which acted as a positive control group. At the end of the exposures, the lungs, colon and liver of the mice were collected and analyzed for increased *cII* mutant frequency. 1-BP did not induce *cII* mutations different from negative control values in any of the three organs examined, while *cII* mutations were increased in all three tissues of the positive control. The authors indicated this was evidence that 1-BP is not a direct acting genotoxic carcinogen.

In their review of 1-BP toxicity, U.S. EPA (2020a) noted some limitations in this study that may have resulted in the negative finding for mutagenicity. The maximum tolerated dose, in the range of 400 to 500 ppm, was not evaluated in the female mice. Also, an exposure time of 28 days, followed by a post-exposure observation period of three days may have been too short to detect mutations in slower dividing tissues. Generally, a post-exposure period of 28 days is recommended to allow fixing of DNA damage into stable mutations in slower dividing tissues. Other limitations included no evaluation of male and female rats, which also exhibited an increase in cancer incidence, or examination of other tissues, such as skin, large intestine and pancreas, which are target sites for tumors in rats. Finally, no carcinogenic/mutagenic structural analogs of 1-BP have been tested with the Big Blue® assay. If negative results were found with 1-BP analogs such as bromoethane, it might be concluded that these assays are not suitable for assessing the mutagenicity of 1-BP.

Table 4. Genotoxicity and mutagenicity study summaries for 1-BP

Cell type or species/strain	Description	Metabolic Activation		Reference
		without	with	
DNA strand-break tests (comet assay or other DNA damage assay)				
Human leukocytes (*in vitro*)	Comet assay	+/-	NA	Toraason *et al.,* (2006)
Human leukocytes of exposed workers (*in vivo*)	Comet assay	+/-	NA	Toraason *et al.,* (2006)
Human HepG2 cells	Hydroxylapatite DNA chromatography	-	NA	Hasspieler *et al*., (2006)
DNA adduct formation				
Calf thymus DNA	N-propyl guanine adduct formation	+	NA	Thapa et al., 2016
Calf thymus DNA	N-propyl guanine adduct formation	+	+	Nepal et al., 2019
Male rats (*in vivo*)	N-propyl guanine adducts in tissues	+	NA	Nepal et al., 2019
Induction of DNA repair (Unscheduled DNA synthesis)				
Human HepG2 cells	[^{3}H]-thymidine incorporation	-	NA	Hasspieler *et al*., (2006)
Bacterial mutation tests				
S. typhimurium	TA98	-	-	Barber *et al.,* (1981)
	TA100	+	+	
	TA1535	+	+	
	TA1537	-	-	
	TA1538	-	-	
S. typhimurium and *E. coli*	TA98, TA100, TA1535, TA1537, E. coli WP2 uvrA	-	-	BioReliance, (2015)
S. typhimurium and *E. coli*	TA97, TA98, TA100, TA1535, and WP2 uvrA/pKM101	-	-	NTP (2011a)
Mammalian cell gene mutation test				
L5178Y mouse lymphoma cells	parental type TK+/- to mutant form TK$^{-/-}$ forward mutation	+	+	Elf Atochem (1996)
Chromosomal damage				
Mouse bone marrow cells (*in vivo*)	Micronuclei after i.p injection	-	NA	Elf Atochem (1995)
Mouse peripheral erythrocytes (*in vivo*)	Micronuclei after 3-month inhalation exposure	-	NA	NTP (2011a)
Transgenic rodent mutation assay				
Big Blue® transgenic female B6C3F1 mice (*in vivo*)	*cII* gene mutation frequency in lung, colon, and liver	-	NA	Stelljes *et al.,* 2019

+/-: equivocal; NA: not applicable

Dominant lethal mutations in rodents

The dominant lethal test identifies germ-cell mutagens by measuring embryonic death of the progeny of treated males caused by an absorbed chemical penetrating gonadal tissue and producing chromosomal breakage in parent germ cells. This test does not detect somatic mutations, so it is not included in Table 4. It also has a low sensitivity for detecting small increases in induced mutation frequency due to a high rate of spontaneous mutations.

Dominant lethal studies were conducted in male Sprague Dawley rats (15/chemical) with 5 halogenated 3-carbon compounds (including 1-BP) that were similar in structure to 1,2-dibromo-3-chloropropane (DBCP), a compound that is known to cause dominant lethal mutations (Saito-Suzuki *et al.*, 1982). Treated males were exposed by gastric intubation to 400 mg/kg 1-BP for 5 consecutive days. Males were then mated with untreated females during ten sequential mating periods of a week each. 1,2,3-Tribromopropane (50 mg/kg daily) acted similarly to DBCP (50 mg/kg) in causing dominant lethal mutations based on dead embryonic implants, especially in the early spermatid stage. 1,2-Dibromopropane (200 mg/kg) gave a minimal response. 1-BP (400 mg/kg), 1,2,3-trichloropropane (80 mg/kg) and 1-chloropropane (1,000 mg/kg) were inactive.

1-BP was administered orally to ICR male mice (20/group) at 300 or 600 mg/kg for 10 days before mating to investigate the potential of 1-BP to induce dominant lethality (Yu *et al.*, 2008). Males were mated with untreated females during six sequential mating periods of a week each. Males were necropsied at the end of mating and the pregnant females on days 15-17 of gestation. A positive control group (40 mg/kg cyclophosphamide administered IP) was included and followed the same mating schedule. There were no treatment-related changes in clinical signs, gross findings, mating index, gestation index, number of corpora lutea and implantations, pre-implantation loss, live fetuses, resorptions, dead fetuses, and post-implantation loss at either 1-BP dose that would indicate dominant lethality. An increase in pre-implantation loss during the fifth week was attributed to treatment-related low sperm quality. In the positive control group mating and gestation indices were normal, but a decrease in the number of implantations and an increase in pre-implantation loss and fetal deaths were observed during the first 2 or 3 weeks, resulting in a markedly increased dominant lethal mutation rate for the first 3 weeks.

Other Supporting Data

Cancer Bioassays with Structurally Related Compounds

Previous long-term rodent toxicology and carcinogenesis studies with brominated hydrocarbons have been conducted by the NTP, which have resulted in tumors in the same organs and tissues as those following 1-BP exposure (see below).

Chronic inhalation exposure of F344 rats and B6C3F$_1$ mice to 1,2-dibromoethane resulted in significantly increased incidences of alveolar/bronchiolar adenomas and carcinomas in male and female mice and female rats (NTP, 1982a). 1,2-Dibromoethane exposure also led to an increased incidence of mesotheliomas of the tunica vaginalis (epididymis) in male rats. Similarly, long-term inhalation exposure of F344 rats and B6C3F$_1$ mice to 1,2-dibromo-3-chloropropane led to increased incidences of alveolar/bronchiolar adenomas and alveolar/bronchiolar adenomas or carcinomas in male and female mice (NTP, 1982b). 1,2-dibromo-3-chloropropane is listed as a Group 2B carcinogen (possibly carcinogenic to humans) by IARC (1987).

In separate two-year oral gavage studies in F344/N rats and B6C3F$_1$ mice treated with bromodichloromethane (NTP, 1987) and tribromomethane (NTP, 1989), significantly increased incidences of adenomatous polyp and adenocarcinoma, and adenomatous polyps or adenocarcinomas (combined), respectively, were observed in the large intestine of male and female rats. The occurrence of this rare tumor following exposure to brominated compounds structurally related to 1-BP strengthened NTPs conclusion for "some evidence" for adenoma of the large intestine in male rats resulting from 1-BP exposure (NTP, 2011).

Genotoxicity of 1-BP metabolites

1-BP metabolites formed by CYP-mediated oxidation in rodents include α-bromohydrin and glycidol (Ishidao *et al.*, 2002; Garner *et al.*, 2007). Both are direct-acting mutagens that induce DNA damage in bacteria (Stolzenberg and Hine, 1979; IARC, 2000). In addition, glycidol has been shown to be mutagenic in mammalian cells, and induce DNA damage and chromosomal damage *in vitro* in rodent and human cells. *In vivo* studies in mice indicate that glycidol induces micronucleus formation but not chromosomal aberrations (IARC, 2000).

Shimamura et al. (2020) investigated the ability of 1-BP to induce the glycidol biomarker *N*-(2,3-dihydroxypropyl)valine, a hemoglobin adduct of glycidol, in mice. The biomarker was not detected in mice 24 hours following a single oral dose of 1-BP. The biomarker was also not detected in mice treated with other glycidol-related chemicals (i.e., epichlorohydrin, propylene oxide, allyl alcohol, fructose, and glyceraldehyde). The authors suggested that the lack of detection of the glycidol

adduct may be a result of analysis prior to formation of the adduct, and the use of a single dose of 1-BP rather than multiple doses.

Immune System, Oxidative Stress, and Cancer

Inflammation is a precursor of many diseases including several types of cancer (Coussens and Werb, 2002; Colotta *et al.*, 2009; Korniluk *et al.*, 2017). In the NTP (2011) carcinogenicity study, 1-BP produced an inflammatory reaction in the respiratory system of rats and mice, but only female mice developed tumors in the lung. Chronic suppurative inflammation was significantly increased in rats in the highest 1-BP exposure group. These lesions were characterized by the presence of Splendore Hoeppli (S-H) material, which were primarily found in the nose and skin of affected animals and typically surrounds or is adjacent to the agent causing S-H bodies (i.e., fungi, helminthes or bacteria). Immunosuppression has been suggested as a cause for the development of these lesions (Morgan *et al.*, 2011). S-H bodies following 1-BP exposure in rats and mice have only occurred in rats, although immunotoxicity tests have shown that both rodent species were immunosuppressed after 1-BP exposure (Anderson *et al.*, 2010). Species differences in the presence of opportunistic bacteria, or differences in innate resistance to infection, have been postulated as possible causes.

Han *et al.* (2008) investigated the proinflammatory effects of 1-BP *in vitro* in mouse macrophages. 1-BP induced the production of nitric oxide (NO) and proinflammatory cytokines, including interleukin (IL)-1β, IL-6, and tumor necrosis factor (TNF)-α in the macrophages. The expression levels of these genes increased in a dose-dependent manner (from 0.5 to 10 micromolar in cell culture). Nuclear transcription factor-κB (NF-κB) sites were identified in the promoter of the inducible nitric oxide synthase (iNOS) and proinflammatory cytokine genes. The authors noted that NO synthesized by iNOS is considered an important mediator of carcinogenesis that may elevate cancer progression, and that overexpressed iNOS has been found in human breast and colorectal tumors (Thomsen *et al.*, 1995; Hao *et al.*, 2001).

1-BP has also been observed to induce oxidative stress and apoptosis in an ovarian carcinoma cell line (OVCAR-3) through inactivation of nuclear factor erythroid 2-related factor 2 (Nrf2), which plays an important role in regulating intracellular antioxidant levels (Yang *et al.*, 2021).

Induction of cancer stem cells in colorectal cancer

Colorectal cancer has a high relapse rate, attributed to the high proportion of cancer stem cells, or self-renewing cells within tumors. Cho et al. (2017) investigated the effects of 1-BP and similar brominated compounds on the “stemness” in human colorectal cancer cell lines

[although not explicitly defined by the authors, OEHHA notes that "stemness" generally refers to a state of a cell characterized by a high degree of plasticity, where plasticity is the property of being transmutable into either a less committed or a more committed state]. 1-BP was observed to increase the spheroid formation in colorectal cancer cells (CSC221, DLD1, Caco2, and HT29 cells) in vitro, which is a measure of the ability to induce cancer cell stemness. 1-BP also induced the expression of cancer stemness markers, including ALDH-1, CD133, Lgr-5, and Msi-1, at both the mRNA and protein levels. Finally, 1-BP was found to increase the transcriptional activity of the Hedgehog, Notch, and Wnt signaling pathways, which supports the hypothesis that induction of cancer cell stemness by 1-BP occurs via these signaling pathways. The authors concluded that 1-BP and other related compounds have the potential to promote cancer stemness.

IV. CANCER HAZARD EVALUATION

The chronic toxicity/carcinogenicity studies by NTP in rats and mice (Morgan *et al.*, 2011; NTP, 2011) are the only source of carcinogenicity data for 1-BP. Although there is human exposure to 1-BP (Ichihara *et al.*, 2004a; Hanley *et al.*, 2006; Hanley *et al.*, 2009; 2010), widespread exposure has occurred only relatively recently. The initial reports of high occupational exposure were based on workers studied in the 1990s (Ichihara *et al.*, 2004a). Human cancer generally has a long latency period, so occupational exposure data of sufficient exposure duration may not yet exist.

Lifetime exposure to 1-BP in rodents resulted in tumors in male and female rats, and female mice (Morgan *et al.*, 2011; NTP, 2011). Tumors that the NTP concluded were a result of 1-BP exposure included adenomas of the large intestine in male and female rats, skin tumors of the epithelium in male rats, and alveolar/bronchiolar adenoma or carcinoma of the lungs in female mice. However, the low incidence of adenoma in the large intestine of male rats resulted in no significant difference relative to controls, and no significant positive trend. The low tumor incidence will not contribute to the overall cancer potency, so OEHHA did not use this particular tumor data to derive a cancer potency. The tumors OEHHA identified as being suitable for cancer potency determination were adenomas of the large intestine in female rats, the combined skin neoplasms of epithelial origin in male rats (keratoacanthoma, basal cell adenoma or carcinoma, and squamous cell papilloma or carcinoma), and lung tumors in female mice (alveolar/bronchiolar adenomas or carcinomas combined).

Supporting data for the carcinogenicity of 1-BP included some evidence for genotoxicity and mutagenicity in cell culture studies. *In vitro* exposure of cultured human leukocytes to 1-BP resulted in equivocal evidence of increased DNA damage by the comet assay (Toraason *et al.*, 2006). 1-BP was mutagenic in a closed system bacterial Ames assay with and without S9, suggesting 1-BP is a direct acting

mutagen (Barber *et al.*, 1981). 1-BP also induced mutations *in vitro* at the thymidine kinase (TK) locus in L5178Y mouse lymphoma cells (Elf Atochem, 1996). Lastly, 1-BP has been shown to produce DNA adducts both *in vitro* and *in vivo* (Thapa, 2016; Nepal *et al.*, 2019)

In addition, long-term rodent exposure studies with structurally-related brominated compounds, including 1,2-dibromoethane, 1,2-dibromo-3-chloropropane, bromodichloromethane and tribromomethane, have resulted in similar tumors as that caused by 1-BP. *In vivo* metabolism of 1-BP resulted in the production of direct acting mutagens such as α-bromohydrin and glycidol in rodents (Ishidao *et al.*, 2002; Garner *et al.*, 2007). Finally, 1-BP increased the "stemness" in human colorectal cancer cell lines.

V. QUANTITATIVE CANCER RISK ASSESSMENT

Effective Tumor Incidences

The effective tumor incidences in rats and mice (Tables 5A and 5B, respectively) were determined from individual animal survival data of the NTP study located in the Chemical Effects in Biological Systems (CEBS) database for rats (NTP-CEBS, 2011a) and mice (NTP-CEBS, 2011b). The effective tumor incidence is the number of tumor-bearing animals (numerator) over the number of animals alive at the time of first occurrence of the tumor (denominator). In most cases, the effective tumor incidences were used to calculate the cancer slope factor for 1-BP. This method of tallying tumor incidence removes animals from the assessment that died before they are considered at risk for tumor development. Tables 5A and 5B do not include treatment-related tumors that were of very low incidence (e.g., large intestine tumors in male rats) or tumors that were of equivocal significance (e.g., malignant mesothelioma and pancreatic islet tumors in male rats, and skin tumors in female rats). Statistical analysis was performed using the Cochran-Armitage trend test and the Fisher exact test as recommended for carcinogen risk assessment (US EPA, 2005).

Table 5A. Adjusted tumor incidence in rats exposed to 1-BP for two years (NTP, 2011b)[a,b]

Sex and Species	Tumor Type	Incidence by concentration				Statistical p-values for pairwise comparison with controls			
		0 ppm, 0 mg/m³	125 ppm, 629 mg/m³	250 ppm, 1258 mg/m³	500 ppm, 2515 mg/m³	Trend[c]	0 ppm, 0 mg/m³	125 ppm, 629 mg/m³	250 ppm, 1258 mg/m³
Male Rats	Skin: Basal Cell Adenoma	0/46	1/42	2/39	1/36	0.191	0.477	0.208	0.439
	Skin: Basal Cell Carcinoma	0/28	2/31	1/26	2/21	0.089	0.272	0.481	0.179
	Skin: Keratoacanthoma	0/49	3/49	6/49*	6/44**	0.006	0.121	0.013	0.009
	Skin: Squamous Cell Carcinoma	1/37	1/34	0/29	2/29	0.881	0.732	1.000	0.408
	Skin: Keratoacanthoma or Squamous Cell Carcinoma	1/49	4/49	6/49	8/44*	0.004	0.181	0.056	0.010
	Skin: Keratoacanthoma, Basal Cell Adenoma, Basal Cell Carcinoma, or Squamous Cell Carcinoma	1/49	7/49*	9/49**	10/44**	0.003	0.030	0.008	0.002
Female Rats	Large Intestine (Colon or Rectum): Adenoma	0/45	1/43	2/41	5/36*	0.001	0.489	0.224	0.015

Table 5B. Adjusted tumor incidence in female mice exposed to 1-BP for two years (NTP, 2011b)[a,b]

Sex and Species	Female Mouse	Incidence by concentration				Statistical p-values for pairwise comparison with controls			
		0 ppm, 0 mg/m³	62.5 ppm, 314 mg/m³	125 ppm, 629 mg/m³	250 ppm, 1258 mg/m³	Trend[c]	62.5 ppm, 314 mg/m³	125 ppm, 629 mg/m³	250 ppm, 1258 mg/m³
Female Mice	Lung: Alveolar/Bronchiolar Adenoma	1/41	6/46	4/42	10/47**	0.006	0.075	0.187	0.007
	Lung: Alveolar/Bronchiolar Carcinoma	0/36	7/42*	5/38*	4/43	0.250	0.010	0.031	0.082
	Lung: Alveolar/Bronchiolar Adenoma or Carcinoma	1/41	9/46*	8/42*	14/47**	0.001	0.012	0.016	<0.001

(a) Incidence ratio after adjusting for intercurrent mortality using the effective number adjustment method (i.e., number alive on day of first tumor).
(b) * = *p*<0.05, ** = *p*<0.01; *p*-value indicators are from pairwise comparisons with controls using Fisher exact tests performed by OEHHA;
(c) p-values in the trend column are for the Cochran-Armitage trend test performed by OEHHA using BMD software (US EPA, 2017b).

Cancer Slope Factor Derivation

For the derivation of the CSF, 1-BP chamber concentrations of 0, 62.5 (mice only), 125, 250 and 500 (rats only) ppm were time-adjusted and converted to mg/m^3 (6.17 hours/24 hours × 5 days/7 days × 5.03 mg/m^3 / ppm) to extrapolate from the intermittent chamber exposure conditions to a continuous exposure over the life span of the animals (*i.e.*, to simulate an annualized average air concentration). The time-adjusted concentrations were 0, 57.73, 115.46, 230.92, and 461.83 mg/m^3.

The average daily dose, in mg/kg BW-day, is used for calculating the cancer potencies. To calculate the daily dose, the average body weight of the rats and mice over the duration of the study is used to determine the inhalation rate (IR). The weighted average lifetime body weights for control rats of both sexes and female mice were calculated from the NTP (2011) study based on the regular reporting of group mean body weights every 1 to 4 weeks during the 2-year exposure. Body weights and daily dose for male mice were not calculated since no 1-BP-related carcinogenicity was observed in male mice. The average body weights were 440.6, 284.9, and 47.4 g for the control male rats, female rats, and female mice, respectively.

A comprehensive analysis of rat minute volume data was undertaken by OEHHA (2018) to update the IR equation by Anderson (1983) and is shown below (Eq. 6-1a). The analysis incorporates studies published since 1988 that more accurately reflect true resting IRs of rats. For mice, the IRs were determined using the equation (Eq. 6-1b) by Anderson (1983). These formulas reflect proportional differences of body weight ($BW^{2/3}$) on the respiratory rate within a species.

Rats: $IR\ (m^3/day) = 0.702\ m^3/day\text{-}kg \times (BW)^{2/3}$ Eq. 6-1a

Mice: $IR\ (m^3/day) = 0.0345\ m^3/day \times (BW / 0.025\ kg)^{2/3}$ Eq. 6-1b

The calculated average daily IRs during the 1-BP exposures are 0.406, 0.304, and 0.0528 m^3/day for male and female rats and female mice, respectively. The average daily doses (shown in Table 6) could then be calculated with the following equation:

Dose (mg/kg BW-day) = IR × C / BW Eq. 6-2

Where:

C = time-adjusted 1-BP concentration (mg/m^3)

Table 6. Calculated average daily exposed dose of 1-BP in rats and mice

Species sex	1-BP Chamber Concentration (mg/m^3)				
	0	**314**	**629**	**1,258**	**2,515**
	Daily Exposed Dose (mg/kg-day)				
Rats					
Males	0	-	106.39	212.78	425.56
Females	0	-	123.20	246.40	492.79
Mice					
Females	0	64.31	128.61	257.22	-

(-): no rat/mouse exposure group at this concentration

The United States Environmental Protection Agency's (US EPA's) Benchmark dose (BMD) methodology and Benchmark Dose Modeling Software (BMDS, version 3.2) were used to perform dose-response extrapolation (US EPA, 2020b). BMD analyses were run for the tumor data that were identified as treatment-related and showed a statistically significant increase above control values and a statistically significant positive trend (See Table 7). Where tumors of the same histological cell type or tissue type (*e.g.*, skin tumors of epithelial origin; pulmonary alveolar/bronchiolar adenomas and carcinomas) are observed, the combined incidence is used for dose-response assessment (McConnell *et al.*, 1986; Brix *et al.*, 2010).

The multistage-cancer polynomial model was fit to the female rat and female mouse data. Survival was unaffected by 1-BP exposure in these groups, so the effective tumor incidences were used to derive the cancer potencies. The multistage Weibull model was used for the male rat tumor data due to decreased survival in the 500 ppm group relative to the control group (OEHHA, 1992; US EPA, 2017b). OEHHA applies this adjustment in lifetime rodent exposure studies when 1) survival is reduced by about 15% or greater compared to controls before week 85, and 2) less than 85% of these early deaths occur in animals that have treatment-related tumors. The 500 ppm group displayed reduced survival of 10-11% between week 70 and week 80. The difference in survival increased to 22% at week 83, and then varied mostly between 16-22% to the end of the study at week 104. Nine of 37 early deaths were due to chronic inflammation in various organs (lung, nose, skin, and bone) that was treatment-related; the remaining early deaths were due to various types of neoplasia that were not treatment-related. Only seven of the male rats that died early had a treatment-related tumor (i.e., large intestine or skin tumor), none of which were the cause of death.

For large datasets such as those by the NTP, a Benchmark Dose Response (BMR) of 5% is recommended by OEHHA (2008) for the BMD, and 95% lower confidence bound (BMDL). First and 2nd degree polynomial multistage models were run for all

suitable tumor data sets, and the most appropriate model fit was chosen based on BMD technical guidance (US EPA, 2012). The degree of polynomial chosen was 1 in all cases.[1] The resulting BMD and BMDL values for each tumor type are shown in Table 7. The rodent CSFs, in units of $(mg/kg\text{-}day)^{-1}$, are calculated as 0.05/BMDL, where 0.05 represents the 5% tumor response, or BMR. The BMDL is calculated in the BMD software and is part of the output results. The rodent CSFs (CSF(a)) were then converted to human equivalents (CSF(h)) by multiplying the CSF(a) by the ratio of human to animal body weights (BW(h) / BW(a)) raised to the one-fourth power when animal potency is expressed in units of $(mg/kg\text{-}day)^{-1}$:

$$CSF(h) = CSF(a) \times (BW(h) / BW(a))^{1/4} \qquad \text{Eq. 6-3}$$

Lifetime body weights for rodents (BW(a)) were calculated from the NTP (2011) study as described above. The default body weight for humans (BW(h)) is 70 kg. The body weight scaling factor assumes that mg/surface area/day is an equivalent dose between species (OEHHA, 2009). Using this interspecies scaling factor is preferred by OEHHA because it is assumed to account not only for pharmacokinetic differences (*e.g.*, breathing rate, metabolism), but also for pharmacodynamic considerations, *i.e.*, tissue responses to chemical exposure (OEHHA, 2005).

When extrapolating to the human equivalent dose using the body weight scaling factor, pulmonary alveolar/bronchiolar adenoma and/or carcinoma combined in female mice provided the highest CSF(h) value of 0.013 $(mg/kg\text{-}day)^{-1}$ (CSFs rounded to two significant figures in the final assessment), establishing this tumor in female mice as the most sensitive endpoint for 1-BP-induced carcinogenicity. The multistage model fit to the female mouse tumor data is shown in Figure 2.

---

[1] For female mice alveolar/bronchiolar tumors (See Table 7 below), BMD guidance suggested a 2nd degree multistage model provided the best fit to the data. However, this choice was based on an Akaike Information Criterion value that was only 0.0000001 lower than the 1st degree multistage model. Due to nearly identical model fits, OEHHA chose the simpler 1st degree model to calculate the BMDL.

Table 7. BMDS Modeling Results

Tumor Type	Sex and Species	Akaike Information Criterion	*p*-value	BMD (mg/kg-day)[a]	BMDL (mg/kg-day)	CSF - Rodent $(mg/kg\text{-}day)^{-1}$	CSF - Human $(mg/kg\text{-}day)^{-1}$
Skin tumors	Male Rats	151.75	NA[a]	57.57	33.43	0.001496	0.0053
Large Intestine	Female Rats	56.84	0.95	202.43	119.07	0.000420	0.0017
Alveolar/ bronchiolar	Female Mice	159.53	0.26	36.34	24.54	0.00204	0.013

[a] Not applicable for the multistage Weibull model



Figure 2. Multistage model plot fit to the female mouse lung tumor data for 1-BP. The Multistage polynomial degree 1 model with BMR of 5% extra risk for the BMD and 95% lower confidence bound (BMDL).

Inhalation Unit Risk Factor

The Inhalation Unit Risk (IUR) describes the excess cancer risk associated with inhalation exposure to a concentration of 1 µg/m^3 and is derived from the human CSF(h):

$$IUR = (CSF(h) \times BR) / (BW \times CF) \qquad \text{Eq. 6-4}$$

Where:

BR = mean human breathing rate (20 m^3/day)
BW = mean human body weight (70 kg)
CF = mg to µg conversion factor of 1,000

Use of the equation above with the 1-BP CSF of 0.013 (mg/kg-day)$^{-1}$ results in a calculated IUR of 0.0000037 (µg/m^3)$^{-1}$, which can also be expressed as 3.7×10^{-6} (µg/m^3)$^{-1}$. Thus, the extra cancer risk associated with continuous lifetime exposure to 1 µg/m^3 1-BP is 3.7 in a million.

For comparison, the only other short-chain brominated alkane that currently has a Hot Spots cancer IUR is 1,2-dibromo-3-choropropane, with a value of 2.0×10^{-3} (µg/m^3)$^{-1}$ (OEHHA, 2009).

VI. CONCLUSIONS

Two-year 1-BP inhalation studies conducted by the NTP established evidence of carcinogenicity in male and female rats, and female mice. Supporting evidence for the carcinogenicity of 1-BP include some positive genotoxic results from *in vitro* studies, a positive *in vivo* study for DNA adduct formation, development of similar tumors in long-term rodent exposure studies by structurally related brominated compounds, and CYP-mediated oxidation of 1-BP to known mutagenic compounds. Rodent CSFs were calculated from the NTP tumor incidence data for each tumor type in each affected species and sex. This was performed by calculating the lower 95% confidence limit on the inhalation concentration associated with a 5% tumor response (BMDL) using the multistage or Weibull cancer models in Benchmark Dose Software (BMDS) version 3.1 (US EPA, 2020b). Linear extrapolation from the BMDL to the origin was used to determine the slope of the dose-response curve for low level exposure, the inhalation CSF. The rodent CSFs were then converted to human equivalent exposure levels using body weight scaling raised to the one-fourth power when animal potency is expressed in units of (mg/kg-day)$^{-1}$. The CSF used for 1-BP, based on the most sensitive species and sex, is 0.013 (mg/kg-day)$^{-1}$ for pulmonary alveolar/bronchiolar adenomas or carcinomas combined in female mice. An IUR of 3.7×10^{-6} (µg/m^3)$^{-1}$ was calculated from the CSF using the assumption of a human breathing rate of 20 m^3/day and an average human body weight of 70 kg.

VII. REFERENCES

Anderson EL (1983). Quantitative approaches in use to assess cancer risk. Risk Analysis 3(4): 277-295.

Anderson SE, Munson AE, Butterworth LF, Germolec D, Morgan DL, Roycroft JA, Dill J and Meade BJ (2010). Whole-body inhalation exposure to 1-bromopropane suppresses the IgM response to sheep red blood cells in female B6C3F1 mice and Fisher 344/N rats. Inhal Toxicol 22(2): 125-32.

Barber ED, Donish WH and Mueller KR (1981). A procedure for the quantitative measurement of the mutagenicity of volatile liquids in the Ames Salmonella/microsome assay. Mutat Res 90(1): 31-48.

BioReliance (2015). Appendix III. Closed-System Ames Test on 1-Bromopropane Conducted at BioReliance and Sponsored by Albermarle Corporation. Final Report. Study No, AD58PU.503001.BTL. Baton Rouge, LA.

Boyle EB, Viet SM, Wright DJ, Merrill LS, Alwis KU, Blount BC, Mortensen ME, Moye J, Jr. and Dellarco M (2016). Assessment of Exposure to VOCs among Pregnant Women in the National Children's Study. Int J Environ Res Public Health 13(4): 376.

Boysen G, Pachkowski BF, Nakamura J and Swenberg JA (2009). The formation and biological significance of N7-guanine adducts. Mutat Res 678(2): 76-94.

Brix AE, Hardisty JF and McConnell EE (2010). Combining neoplasms for evaluation of rodent carcinogenesis studies. In: Cancer Risk Assessment, C-H Hsu and T Stedeford eds., John Wiley & Sons, Inc. pp. 619-715.

CARB (2011). Development of Updated ARB Solvent Cleaning Emissions Inventories, Final Report, Agreement No. 06-322. California Air Resources Board, Sacramento ,CA. Online at: https://www.arb.ca.gov/research/apr/past/06-322.pdf.

CARB (2015). Alternative Solvents: Health and Environmental Impacts. California Air Resources Board, Sacramento, CA Online at: https://www.arb.ca.gov/toxics/dryclean/notice2015_alt_solvents.pdf.

Cheever KL, Marlow KL, B'Hymer C, Hanley KW and Lynch DW (2009). Development of an HPLC-MS procedure for the quantification of N-acetyl-S-(n-propyl)-l-cysteine, the major urinary metabolite of 1-bromopropane in human urine. J Chromatogr B Analyt Technol Biomed Life Sci 877(8-9): 827-32.

Cho YC, Nguyen TT, Park SY, Kim K, Kim HS, Jeong HG, Kim KK and Kim H (2017). Bromopropane Compounds Increase the Stemness of Colorectal Cancer Cells. Int J Mol Sci 18(9).

Colotta F, Allavena P, Sica A, Garlanda C and Mantovani A (2009). Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30(7): 1073-81.

Coussens LM and Werb Z (2002). Inflammation and cancer. Nature 420(6917): 860-7.

Cresteil T (1998). Onset of xenobiotic metabolism in children: toxicological implications. Food Addit Contam 15 Suppl: 45-51.

Elf Atochem (1995). Micronucleus Test by Intraperitoneal Route in Mice. N-Propyl Bromide. Study No. 12122 Mas. Miserey, France: Elf Atochem Société Anonyme, Centre International de Toxicologie.

Elf Atochem (1996). In Vitro Mammalian Cell Gene Mutation Test in L5178 TK+/- Mouse Lymphoma Cells of N-Propyl Bromide. Study No. 13293. Centre International de Toxicologie, Miserey, France.

Garner CE, Liang S, Yin L and Yu X (2015). Physiologically based pharmacokinetic modeling for 1-bromopropane in F344 rats using gas uptake inhalation experiments. Toxicol Sci 145(1): 23-36.

Garner CE, Sloan C, Sumner SC, Burgess J, Davis J, Etheridge A, Parham A and Ghanayem BI (2007). CYP2E1-catalyzed oxidation contributes to the sperm toxicity of 1-bromopropane in mice. Biol Reprod 76(3): 496-505.

Garner CE, Sumner SC, Davis JG, Burgess JP, Yueh Y, Demeter J, Zhan Q, Valentine J, Jeffcoat AR, Burka LT and Mathews JM (2006). Metabolism and disposition of 1-bromopropane in rats and mice following inhalation or intravenous administration. Toxicol Appl Pharmacol 215(1): 23-36.

Garner CE and Yu X (2014). Species and sex-dependent toxicokinetics of 1-bromopropane: the role of hepatic cytochrome P450 oxidation and glutathione (GSH). Xenobiotica 44(7): 644-56.

Guyton KZ, Kyle AD, Aubrecht J, Cogliano VJ, Eastmond DA, Jackson M, Keshava N, Sandy MS, Sonawane B, Zhang L, Waters MD and Smith MT (2009). Improving prediction of chemical carcinogenicity by considering multiple mechanisms and applying toxicogenomic approaches. Mutat Res 681(2-3): 230-40.

Han EH, Hwang YP, Lee KJ, Jeong TC and Jeong HG (2008). 1-Bromopropane induces macrophage activation via extracellular signal-regulated kinase 1/2 MAPK and NF-kappaB pathways. Cancer Lett 262(1): 28-36.

Hanley KW, Petersen M, Curwin BD and Sanderson WT (2006). Urinary bromide and breathing zone concentrations of 1-bromopropane from workers exposed to flexible foam spray adhesives. Ann Occup Hyg 50(6): 599-607.

Hanley KW, Petersen MR, Cheever KL and Luo L (2009). N-acetyl-S-(n-propyl)-l-cysteine in urine from workers exposed to 1-bromopropane in foam cushion spray adhesives. Ann Occup Hyg 53(7): 759-69.

Hanley KW, Petersen MR, Cheever KL and Luo L (2010). Bromide and N-acetyl-S-(n-propyl)-L-cysteine in urine from workers exposed to 1-bromopropane solvents from vapor degreasing or adhesive manufacturing. Int Arch Occup Environ Health 83(5): 571-84.

Hao XP, Pretlow TG, Rao JS and Pretlow TP (2001). Inducible nitric oxide synthase (iNOS) is expressed similarly in multiple aberrant crypt foci and colorectal tumors from the same patients. Cancer Res 61(2): 419-22.

Haseman JK (1983). A reexamination of false-positive rates for carcinogenesis studies. Fundam Appl Toxicol 3(4): 334-9.

Haseman JK (1990). Use of statistical decision rules for evaluating laboratory animal carcinogenicity studies. Fundam Appl Toxicol 14(4): 637-48.

Hasspieler B, Haffner D, Stelljes M and Adeli K (2006). Toxicological assessment of industrial solvents using human cell bioassays: assessment of short-term cytotoxicity and long-term genotoxicity potential. Toxicol Ind Health 22(7): 301-15.

Hines RN (2007). Ontogeny of human hepatic cytochromes P450. J Biochem Mol Toxicol 21(4): 169-75.

IARC (1987). IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Overall Evaluations of Carcinogenicity: An Updating of *IARC Monographs* Volumes 1 to 42, Supplement 7. International Agency for Research on Cancer (IARC). World Health Organization, Lyon, France.

IARC (2000). IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Volume 77, Some Industrial Chemicals. Glycidol. International Agency for Research on Cancer. Lyon, France, pp. 469-486.

IARC (2018). IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Some Industrial Chemicals. International Agency for Research on Cancer (IARC). World Health Organization. Vol. 115. 1-Bromopropane, pp. 37-72. Online at: https://monographs.iarc.fr/wp-content/uploads/2018/06/mono115.pdf.

Ichihara G, Li W, Ding X, Peng S, Yu X, Shibata E, Yamada T, Wang H, Itohara S, Kanno S, Sakai K, Ito H, Kanefusa K and Takeuchi Y (2004a). A survey on exposure level, health status, and biomarkers in workers exposed to 1-bromopropane. Am J Ind Med 45(1): 63-75.

Ikeda M (1999). Solvents in urine as exposure markers. Toxicol Lett 108(2-3): 99-106.

Ishidao T, Kunugita N, Fueta Y, Arashidani K and Hori H (2002). Effects of inhaled 1-bromopropane vapor on rat metabolism. Toxicol Lett 134(1-3): 237-43.

Jain RB (2015). Levels of selected urinary metabolites of volatile organic compounds among children aged 6-11 years. Environ Res 142: 461-70.

Johnsrud EK, Koukouritaki SB, Divakaran K, Brunengraber LL, Hines RN and McCarver DG (2003). Human hepatic CYP2E1 expression during development. J Pharmacol Exp Ther 307(1): 402-7.

Kawai T, Takeuchi A, Miyama Y, Sakamto K, Zhang ZW, Higashikawa K and Ikeda M (2001). Biological monitoring of occupational exposure to 1-bromopropane by means of urinalysis for 1-bromopropane and bromide ion. Biomarkers 6(5): 303-12.

Konkle SL, Zierold KM, Taylor KC, Riggs DW and Bhatnagar A (2020). National secular trends in ambient air volatile organic compound levels and biomarkers of exposure in the United States. Environ Res 182: 108991.

Korniluk A, Koper O, Kemona H and Dymicka-Piekarska V (2017). From inflammation to cancer. Ir J Med Sci 186(1): 57-62.

Lee SK, Jeon TW, Kim YB, Lee ES, Jeong HG and Jeong TC (2007). Role of glutathione conjugation in the hepatotoxicity and immunotoxicity induced by 1-bromopropane in female BALB/c mice. J Appl Toxicol 27(4): 358-67.

Liu F, Ichihara S, Mohideen SS, Sai U, Kitoh J and Ichihara G (2009). Comparative study on susceptibility to 1-bromopropane in three mice strains. Toxicol Sci 112(1): 100-10.

Louis LM, Kavi LK, Boyle M, Pool W, Bhandari D, De Jesus VR, Thomas S, Pollack AZ, Sun A, McLean S, Rule AM and Quiros-Alcala L (2021). Biomonitoring of volatile organic compounds (VOCs) among hairdressers in salons primarily serving women of color: A pilot study. Environ Int 154: 106655.

Mathias PI and B’hymer C (2016). Mercapturic acids: recent advances in their determination by liquid chromatography/mass spectrometry and their use in toxicant metabolism studies and in occupational and environmental exposure studies. Biomarkers 21(4): 293-315.

Mathias PI, Cheever KL, Hanley KW, Marlow KL, Johnson BC and B'Hymer C (2012). Comparison and evaluation of urinary biomarkers for occupational exposure to spray adhesives containing 1-bromopropane. Toxicol Mech Methods 22(7): 526-32.

McConnell EE, Solleveld HA, Swenberg JA and Boorman GA (1986). Guidelines for combining neoplasms for evaluation of rodent carcinogenesis studies. J Natl Cancer Inst 76(2): 283-9.

Miao R, Ding B, Zhang Y, Zhao R, Li Y and Zhu B (2018). Large-scale label-free proteomics analysis of occupational poisoned patients of 1-bromopropane, workers exposed to 1-bromopropane and healthy individuals. Hum Exp Toxicol 37(1): 3-12.

Morgan DL, Nyska A, Harbo SJ, Grumbein SL, Dill JA, Roycroft JH, Kissling GE and Cesta MF (2011). Multisite carcinogenicity and respiratory toxicity of inhaled 1-bromopropane in rats and mice. Toxicol Pathol 39(6): 938-48.

Nepal MR, Noh K, Shah S, Bist G, Lee ES and Jeong TC (2019). Identification of DNA and glutathione adducts in male Sprague-Dawley rats exposed to 1-bromopropane. J Toxicol Environ Health A 82(8): 502-513.

NTP-CEBS (2011a). NTP Technical Report on the Toxicology and Carcinogenesis Studies of 1-Bromopropane (CAS No. 106-94-5) in F344/N Rats and B6C3F1 Mice (Inhalation Studies). Chemical Effects in Biological Systems (CEBS). Research Triangle Park, NC (USA): National Toxicology Program. Accessed November 2017. https://tools.niehs.nih.gov/cebs3/ntpViews/?studyNumber=002-01113-0013-0000-2.

NTP-CEBS (2011b). NTP Technical Report on the Toxicology and Carcinogenesis Studies of 1-Bromopropane (CAS No. 106-94-5) in F344/N Rats and B6C3F1 Mice (Inhalation Studies). Chemical Effects in Biological Systems (CEBS). Research Triangle Park, NC (USA): National Toxicology Program. Accessed November 2017. https://tools.niehs.nih.gov/cebs3/ntpViews/?studyNumber=002-01113-0014-0000-3.

NTP (1982a). Carcinogenesis Bioassay of 1,2-Dibromoethane (CAS No. 106-93-4) in F344 Rats and B6C3F1 Mice (Inhalation Study). NTP TR 210. Research Triangle Park, NC.

NTP (1982b). Carcinogenesis Bioassay of 1,2-Dibromo-3-Chloropropane (CAS No. 96-12-8) in F344 Rats and B6C3F1 Mice (Inhalation Study). NTP TR 206. Research Triangle Park, NC.

NTP (1987). Toxicology and Carcinogenesis Studies of Bromodichloromethane (CAS No. 75-27-4) in F344/N Rats and B6C3F1 Mice (Gavage Studies). NTP TR 321. Research Triangle Park, NC.

NTP (1989). Toxicology and Carcinogenesis Studies of Tribromomethane (Bromoform) (CAS No. 75-25-2) in F344/N Rats and B6C3F1 Mice (Gavage Studies). NTP TR 350. Research Triangle Park, NC.

NTP (2003). NTP-CERHR Monograph on the Potential Reproductive and Developmental Effects of 1-Bromopropane. NIH Publication 04-4479. National Toxicology Program-Center for the Evaluation of Risks to Human Reproduction. Online at: https://ntp.niehs.nih.gov/ntp/ohat/bromopropanes/1-bromopropane/1bp_monograph.pdf.

NTP (2011). NTP Technical Report on the Toxicology and Carcinogenesis Studies of 1-Bromopropane (CAS No. 106-94-5) in F344/N Rats and B6C3F1 Mice (Inhalation Studies). NTP TR 471. Research Triangle Park, NC.

NTP (2013). Report on Carcinogens. Monograph on 1-Bromopropane. National Toxicology Program. Online at: https://ntp.niehs.nih.gov/pubhealth/roc/listings/index.html#B.

OEHHA (1992). Expedited Cancer Potency Values and Proposed Regulatory Levels for Certain Proposition 65 Carcinogens. Office of Environmental Health Hazard Assessment, California Environmental Protection Agency. Online at: https://oehha.ca.gov/media/downloads/proposition-65/report/expcancer.pdf.

OEHHA (2005). Air Toxics Hot Spots Program Risk Assessment Guidelines. Part II. Technical Support Document for Describing Available Cancer Potency Factors. California Environmental Protection Agency Office of Environmental Health Hazard Assessment.

OEHHA (2008). Air Toxics Hot Spots Program Risk Assessment Guidelines. Technical Support Document for the Derivation of Noncancer Reference Exposure Levels. California Environmental Protection Agency, Office of Environmental Health Hazard Assessment, Oakland, CA. Online at: http://www.oehha.ca.gov/air/hot_spots/rels_dec2008.html.

OEHHA (2009). Air Toxics Hot Spots Program Risk Assessment Guidelines. Technical Support Document for Cancer Potency Factors: Methodologies for derivation, listing of available values, and adjustments to allow for early life stage exposures. California Environmental Protection Agency Office of Environmental Health Hazard Assessment. Online at: http://oehha.ca.gov/air/crnr/technical-support-document-cancer-potency-factors-2009.

OEHHA (2018). Calculation of rat breathing rate based on bodyweight. California Environmental Protection Agency, Office of Environmental Health Hazard Assessment. Online at: https://oehha.ca.gov/media/downloads/crnr/calcuratbreathingrate092818.pdf.

OEHHA (2021a). Office of Environmental Health Hazard Assessment. The Proposition 65 List. Online at: https://oehha.ca.gov/proposition-65/proposition-65-list.

PubChem (2020). National Library of Medicine, National Center for Biotechnology Information, Bethesda, MD. Last accessed October 2020 at URL: https://pubchem.ncbi.nlm.nih.gov/compound/7840.

PubMed (1996). National Library of Medicine, National Center for Biotechnology Information. Online at: https://pubmed.ncbi.nlm.nih.gov.

Saito-Suzuki R, Teramoto S and Shirasu Y (1982). Dominant lethal studies in rats with 1,2-dibromo-3-chloropropane and its structurally related compounds. Mutat Res 101(4): 321-7.

Shimamura Y, Inagaki R, Honda H and Masuda S (2020). Does External Exposure of Glycidol-Related Chemicals Influence the Forming of the Hemoglobin Adduct, N-(2,3-dihydroxypropyl)valine, as a Biomarker of Internal Exposure to Glycidol? Toxics 8(4).

Stelljes M, Young R and Weinberg J (2019). 28-Day somatic gene mutation study of 1-bromopropane in female Big Blue((R)) B6C3F1 mice via whole-body inhalation: Support for a carcinogenic threshold. Regul Toxicol Pharmacol 104: 1-7.

Stolzenberg SJ and Hine CH (1979). Mutagenicity of halogenated and oxygenated three-carbon compounds. J Toxicol Environ Health 5(6): 1149-58.

Thapa P, Kim, E.-K., Nepal, M. J., Jeong, K. S., Kang, M. J., Noh, K., Lee, S., Jeong, H. G., Lee, J.-H., Jeong, T. C., Lee, E.-S. (2016). Identification of a N^7-guanine adduct of 1-bromopropane in calf thymus DNA by mass spectrometry. Mol Cell Toxicol 12: 7-14.

Thomsen LL, Miles DW, Happerfield L, Bobrow LG, Knowles RG and Moncada S (1995). Nitric oxide synthase activity in human breast cancer. Br J Cancer 72(1): 41-4.

Toraason M, Lynch DW, DeBord DG, Singh N, Krieg E, Butler MA, Toennis CA and Nemhauser JB (2006). DNA damage in leukocytes of workers occupationally exposed to 1-bromopropane. Mutat Res 603(1): 1-14.

TRI (2015). Toxics Release Inventory (TRI) Program. Addition of 1-Bromopropane. United States Environmental Protection Agency. Online at: https://www.epa.gov/toxics-release-inventory-tri-program/addition-1-bromopropane.

US EPA (2005). Guidelines for Carcinogen Risk Assessment, EPA/630/P-03/001B: Risk Assessment Forum, Washington, DC., United States Environmental Protection Agency. Online at: https://www.epa.gov/sites/default/files/2013-09/documents/cancer_guidelines_final_3-25-05.pdf.

US EPA (2012). Benchmark Dose Technical Guidance. United States Environmental Protection Agency. National Center for Environmental Assessment. Online at: https://www.epa.gov/risk/benchmark-dose-technical-guidance.

US EPA (2017a). Preliminary Information on Manufacturing, Processing, Distribution, Use, and Disposal: 1-Bromopropane. Support document for Docket EPA-HQ-OPPT-2016-0741, February 201., Office of Chemical Safety and Pollution Prevention, U.S. EPA. Online at: https://www.epa.gov/sites/default/files/2017-02/documents/1-bromopropane.pdf.

US EPA (2017b). Benchmark Dose Software, Version 2.7. United States Environmental Protection Agency. National Center for Environmental Assessment. Online at: http://www.epa.gov/bmds.

US EPA (2020a). Risk evaluation for 1-bromopropane (*n*-propyl bromide) CASRN: 106-94-5 (EPA 740-R1-8013). United States Environmental Protection Agency. Washington DC.

US EPA (2020b). US EPA Benchmark Dose Software (BMDS) Version 3.2. National Center for Environmental Assessment, US EPA. Available from: https://www.epa.gov/bmds.

US EPA (2022). Clean Air Act Section 112 List of Hazardous Air Pollutant: Amendments to the List of Hazardous Air Pollutants (HAP), 40 CFR Part 63, January 5, 2022, Online at: https://www.govinfo.gov/content/pkg/FR-2022-01-05/pdf/2021-28315.pdf. Federal Register 87(3): 393-96.

Valentine H, Amarnath K, Amarnath V, Li W, Ding X, Valentine WM and Ichihara G (2007). Globin s-propyl cysteine and urinary N-acetyl-S-propylcysteine as internal biomarkers of 1-bromopropane exposure. Toxicol Sci 98(2): 427-35.

van Welie RT, van Dijck RG, Vermeulen NP and van Sittert NJ (1992). Mercapturic acids, protein adducts, and DNA adducts as biomarkers of electrophilic chemicals. Crit Rev Toxicol 22(5-6): 271-306.

Vieira I, Sonnier M and Cresteil T (1996). Developmental expression of CYP2E1 in the human liver. Hypermethylation control of gene expression during the neonatal period. Eur J Biochem 238(2): 476-83.

Yang G, Xiang Y, Zhou W, Zhong X, Zhang Y, Lin D and Huang X (2021). 1-Bromopropane-induced apoptosis in OVCAR-3 cells via oxidative stress and inactivation of Nrf2. Toxicol Ind Health 37(2): 59-67.

Yang W (2020). Organic Gas Speciation Profiles for Consumer Products (2020 Update), California Air Resources Board, Air Quality Planning and Science Division, November 23, 2020, Online at: https://www.arb.ca.gov/ei/speciate/profilereference/og_profiles_for_consumer_products_2020update.pdf.

Yu WJ, Kim JC and Chung MK (2008). Lack of dominant lethality in mice following 1-bromopropane treatment. Mutat Res 652(1): 81-7.